Patent Grant
10842671
1. Field of the Inventions
The present inventions generally relate to surgical methods, implantation devices, and shunts that can be used to treat glaucoma.
2. Description of the Related Art
Glaucoma is a disease of the eye that affects millions of people. Glaucoma is associated with an increase in intraocular pressure resulting either from a failure of a drainage system of an eye to adequately remove aqueous humor from an anterior chamber of the eye or overproduction of aqueous humor by a ciliary body in the eye. Build-up of aqueous humor and resulting intraocular pressure may result in irreversible damage to the optic nerve and the retina, which may lead to irreversible retinal damage and blindness. Glaucoma affects 1 in 200 people aged fifty and younger, and 1 in 10 over the age of eighty for a total of approximately 70 million people worldwide, and glaucoma is the second leading cause of blindness in the world.
There are two main types of glaucoma, “open angle” and “closed angle” glaucoma. Open angle glaucoma refers to glaucoma cases in which intraocular pressure increases but an anterior chamber angle (drainage angle) of an eye remains open. A common cause of open angle glaucoma is blockage in the trabecular meshwork, the fluid flow pathways that normally drain aqueous humor from the anterior chamber of the eye. Closed angle glaucoma refers to glaucoma cases in which intraocular pressure increases due to partial or complete closure of the anterior chamber angle. In closed angle glaucoma, swelling or movement of the iris closes the anterior chamber angle and blocks fluid from accessing to the trabecular meshwork, which in turn obstructs outflow of the aqueous humor from the eye.
Generally, glaucoma may be treated by surgical intervention that involves placing a shunt in the eye to result in production of fluid flow pathways between the anterior chamber and various structures of the eye involved in aqueous humor drainage (e.g., Schlemm's canal, the sclera, or the subconjunctival space). Such fluid flow pathways allow for aqueous humor to exit the anterior chamber. Generally, the surgical intervention to implant the shunt involves inserting into the eye a delivery device that holds an intraocular shunt, and deploying the shunt within the eye.
A delivery device holding the shunt enters the eye through a cornea (ab interno approach), and is advanced across the anterior chamber. The delivery device is advanced through the sclera until a distal portion of the device is in proximity to a drainage structure of the eye. The shunt is then deployed from the delivery device, producing a conduit between the anterior chamber and various structures of the eye involved in aqueous humor drainage (e.g., Schlemm's canal, the sclera, or the subconjunctival space). See for example, Yu et al. (U.S. Pat. No. 6,544,249 and U.S. Pat. Pub. No. 2008/0108933) and Prywes (U.S. Pat. No. 6,007,511). Such fluid flow pathways allow for aqueous humor to exit the anterior chamber, thereby reducing IOP.
Such a surgical procedure requires an optical apparatus, such as a goniolens, so that a surgeon may visualize the delivery device within the eye and ensure proper placement of the shunt after it has been deployed from the delivery device.
Further, various manual and automated deployment devices for implanting an intraocular shunt have been described. See, for example, U.S. Pat. No. 6,544,249 and U.S. Pat. Pub. No. 2008/0108933. Most deployment devices are coupled to a hollow needle which holds the intraocular shunt. Whether an ab externo approach or an ab interno approach is used, the needle is inserted into the eye to deploy the intraocular shunt into the eye. The needle is then withdrawn from the eye.
A problem with treating closed angle glaucoma with surgical intervention is that the closed anterior chamber angle prevents an operator from advancing the deployment device into the anterior chamber angle, and thus the device cannot be properly positioned to deploy an intraocular shunt.
The present inventions generally relate, among other things, to methods for treating closed angle glaucoma that involve using a deployment device that is configured to both re-open a partially or completely closed anterior chamber angle and deploy an intraocular shunt. By re-opening the anterior chamber angle, the deployment device is provided access to the anterior chamber angle so that an operator may properly position the device to deploy the intraocular shunt, thereby generating a fluid flow pathway for outflow of aqueous humor from an anterior chamber of an eye.
In certain aspects, some methods involve inserting into an eye a deployment device configured to hold an intraocular shunt, using the device to re-open an at least partially closed anterior chamber angle of an eye, and deploying the shunt from the device. Deploying the shunt results in a flow path from an anterior chamber of the eye to an area of lower pressure. Exemplary areas of lower pressure include intra-Tenon's space, the subconjunctival space, the episcleral vein, the subarachnoid space, the suprachoroidal space, Schlemm's canal, or drainage structures associated with the intra-scleral space.
In other aspects, some methods involve inserting into an eye a deployment device configured to hold an intraocular shunt, advancing the device such that a protrusion on a distal end of the device advances into an at least partially closed anterior chamber angle of the eye, thereby re-opening the closed angle, and deploying the shunt from the device. In certain embodiments, a distal portion of the device includes a sleeve and a hollow shaft that is movable within the sleeve.
The present inventions generally provide improved shunts that facilitate drainage of fluid from an organ. Particularly, some embodiments of the shunt address and solve the problems with intraocular shunts.
The present inventions also generally relate to devices for deploying intraocular shunts from a delivery device without use of an optical apparatus that contacts the eye, preferably without use of any optical apparatus. Some devices accomplish shunt deployment without use of an optical apparatus by having a biased distal portion, such that upon entry of the distal portion of the device into an anterior chamber of an eye, the distal portion slides to fit within the anterior chamber angle of the eye. A resistance feedback feature of the device informs an operator that the deployment device is properly positioned within the anterior chamber angle of the eye for deployment and proper placement of the shunt within the eye.
In particular embodiments, some methods involve inserting into an eye a deployment device configured to hold an intraocular shunt, determining that a distal portion of the device is properly positioned within the eye without use of an optical apparatus that contacts the eye, and deploying the shunt from the device. In certain embodiments, determining involves advancing the device until a resistance is encountered. The resistance indicates to an operator that a distal end of the device has advanced across the anterior chamber of the eye and that a distal portion of the device is fitted within an anterior chamber angle of the eye, and is thereby properly positioned for deployment of the intraocular shunt.
Another aspect of some embodiments provides methods for deploying a shunt within an eye including inserting into an eye a deployment device configured to hold an intraocular shunt, advancing the device until a protrusion on a distal end of a housing of the device contacts an anterior chamber angle of the eye, thereby providing resistance against further advancement of the device, and deploying the shunt from the device. In certain embodiments, a distal portion of the housing comprises a sleeve and a hollow shaft that is movable within the sleeve.
In certain embodiments, some devices include a housing having an angled distal end, a deployment mechanism at least partially disposed within the housing, and a hollow shaft coupled to the deployment mechanism, in which the shaft is configured to hold an intraocular shunt. Some devices may further include an intraocular shunt that is at least partially disposed within the shaft. In particular embodiments, the angle of the distal end is substantially identical to an anterior chamber angle of an eye.
The housing of some devices may include a proximal portion and a distal portion. In certain embodiments, the distal portion of the housing is movable within the proximal portion of the housing. The housing may further include a member that limits axial retraction of the distal portion of the housing.
In certain embodiments, the distal portion includes a capsule and a sleeve. In other embodiments, a distal end of the sleeve further includes a protrusion. The protrusion may be formed integrally with the distal end of the sleeve or may be connected to a distal end of the sleeve. The protrusion may surround the distal end of the sleeve, or the protrusion may extend around only a portion of the sleeve. In certain embodiments, the protrusion is a collar that surrounds the distal end of the sleeve. In other embodiments, the protrusion includes a flat bottom portion and an angled top portion. In particular embodiments, the angle of the top portion is substantially identical to an anterior chamber angle of an eye.
Some methods and devices are typically conducted using an ab interno approach. Such an approach is contrasted with an ab externo approach, which involves inserting a deployment device through the conjunctiva of the eye. Although, some methods may be conducted using an ab externo approach.
Some methods may be performed such that the distal portion of the deployment device or shaft is inserted above or below the corneal limbus. Some methods may be performed such that the distal portion of the deployment device or shaft is inserted into the eye without removing an anatomical feature of the eye, such as the trabecular meshwork, the iris, the cornea, and the aqueous humor. In certain embodiments, some methods may be conducted without inducing substantial ocular inflammation such as, for example, subconjunctival blebbing or endophthalmitis.
The deployment configuration involves engagement of the deployment mechanism. In certain embodiments, the deployment mechanism may include a two stage system. The first stage is a pusher component and the second stage is a retraction component. Rotation of the deployment mechanism sequentially engages the pusher component and then the retraction component. The pusher component pushes the shunt to partially deploy the shunt from within the shaft, and the retraction component retracts the shaft from around the shunt. The deployment mechanism further includes at least one member that limits axial movement of the shaft.
The hollow shaft of the deployment device may have various shapes and sizes. In certain embodiments, a distal end of the shaft is beveled. In particular embodiments, the bevel is a double bevel. In certain embodiments, the angle of the bevel is such that upon insertion of the shaft through the sclera of an eye, the bevel is substantially parallel with the conjunctiva of an eye. In certain embodiments, the hollow shaft is a needle.
Some devices may be completely automated, partially automated, or completely manual. Some devices may be connected to larger robotic systems or may be used as stand-alone handheld deployment devices. In particular embodiments, the device is a handheld device.
Some devices may include an indicator that provides feedback to an operator as to the state of the deployment mechanism. The indicator may be any type of indicator known in the art, for example a visual indicator, an audio indicator, or a tactile indicator. In certain embodiments, the indicator is a visual indicator.
Other aspects of some embodiments provide devices for deploying an intraocular shunt that include a housing, in which a distal end of the housing includes a protrusion, a deployment mechanism at least partially disposed within the housing, and a hollow shaft coupled to the deployment mechanism, in which the shaft is configured to hold an intraocular shunt. The devices may further include an intraocular shunt that is at least partially disposed within the shaft.
Another aspect of some embodiments provides devices for deploying an intraocular shunt that include a deployment mechanism, a hollow shaft coupled to the deployment mechanism and configured to hold an intraocular shunt, and a member adapted to provide resistance feedback to an operator upon a distal portion of the device contacting an anatomical feature of the eye, such as the sclera. The resistance feedback indicates to an operator that a distal portion of the device is properly positioned to deploy the shunt.
Another aspect of some embodiments provides devices for deploying an intraocular shunt that include a deployment mechanism, a hollow shaft coupled to the deployment mechanism and configured to hold an intraocular shunt, and means for providing feedback to an operator advancing the shaft. The feedback indicates to an operator that a distal portion of the shaft is properly positioned to deploy the shunt. In certain embodiments, the feedback is resistance feedback.
Other aspects of some embodiments provide devices for deploying an intraocular shunt including a housing having a proximal portion and a distal portion, in which the distal portion is movable within the proximal portion, a deployment mechanism at least partially disposed within the housing, and a hollow shaft coupled to the deployment mechanism, in which the shaft is configured to hold an intraocular shunt. The devices may further include an intraocular shunt that is at least partially disposed within the shaft.
Some devices include numerous configurations, such as an insertion configuration, a shaft exposure configuration, and a deployment configuration. The insertion configuration includes the hollow shaft fully disposed within the sleeve. The shaft exposure configuration includes retraction of the capsule to at least partially within the proximal portion of the housing, thereby exposing a distal portion of the hollow shaft from the sleeve.
Other aspects of some embodiments provide devices for deploying an intraocular shunt that includes a housing, a deployment mechanism at least partially disposed within the housing, and a hollow shaft coupled inside the housing to the deployment mechanism, in which the shaft is configured to hold an intraocular shunt. These devices include an insertion configuration and a deployment configuration and the insertion configuration involves the shaft being fully disposed within the housing. The devices may further include an intraocular shunt that is at least partially disposed within the shaft.
Further, some embodiments relate to eliminating or at least minimizing damage to the eye of a patient during an intraocular shunt placement procedure. Intraocular shunts are typically deployed into the eye using a deployment device that includes or is coupled to a hollow shaft, such as a needle, that holds the intraocular shunt. The hollow shaft of the deployment device is inserted into the eye, then the shunt is deployed into the eye from the deployment device. Once inserted into the eye, the interaction between the hollow shaft of the deployment device and surrounding eye tissue oftentimes causes the shaft to become stuck in the surrounding eye tissue (due to frictional resistance, for example), which can cause severe eye trauma upon shunt deployment or withdrawal of the shaft from the eye. This trauma is avoided or at least minimized in some embodiments by loosening the hollow shaft from the surrounding eye tissue prior to deploying the shunt into the eye from the deployment device and/or withdrawing the hollow shaft from the eye.
The present inventions provide improved methods for implantation of intraocular shunts. In one aspect, some methods involve the insertion into the eye of a portion of a deployment device comprising an intraocular shunt, loosening the portion of deployment device from the surrounding eye tissue, deploying the shunt into the eye from the deployment device, then withdrawing the portion of the deployment device from the eye. In one particular embodiment, the methods involve inserting into the eye a portion of a deployment device comprising an intraocular shunt without removing an anatomical feature of the eye, loosening the portion of the deployment device from the surrounding eye tissue, deploying the shunt into the eye from the deployment device, then withdrawing the portion of the deployment device from the eye. Loosening of the portion of the deployment device inserted into the eye from the surrounding eye tissue can be achieved, for example, by rotating the deployment device or a portion of the deployment device, other than the portion inserted into the eye. Rotation of the deployment device, or portion thereof, causes the portion of the deployment device inserted into the eye to also rotate, thereby loosening the deployment device from the surrounding eye tissue. Examples of eye tissue surrounding the portion of the deployment device inserted into the eye include, without limitation, the scleral tissue and/or the trabecular meshwork.
The loosening and deployment steps of some methods do not have to be conducted in any particular order. For example, some methods may involve inserting into the eye a portion of a deployment device comprising an intraocular shunt, deploying the shunt into the eye from the deployment device, loosening the portion of the deployment device from the surrounding eye tissue, then withdrawing the portion of the deployment device from the eye.
The deployment device may be configured such that a proximal portion of the deployment device is rotated to loosen the portion of the deployment device in the eye from the surrounding eye tissue before or after deploying the shunt into the eye. Alternatively, the deployment device may be configured such that a distal portion of the deployment device is rotated to loosen the portion of the deployment device in the eye from the surrounding eye before or after deploying the shunt into the eye. In yet another embodiment, the entire deployment device may be rotated to loosen the portion of the deployment device in the eye from the surrounding eye tissue before or after deploying the shunt into the eye. Preferably, the deployment device, or a portion thereof, is rotated about its longitudinal axis. Rotation can be in a clockwise or counterclockwise direction.
In another aspect, the present inventions relate to methods for implanting an intraocular shunt into an eye by inserting into the eye a portion of a deployment device comprising an intraocular shunt, whereby insertion into the eye is at an angle above or below the corneal limbus, rather than through the corneal limbus. Preferably, the portion of the deployment device is inserted into the eye at an angle above the corneal limbus. For example, a portion of a deployment device comprising an intraocular shunt is inserted into the eye approximately 1 mm to 2 mm above the corneal limbus, or any specific value within said range, e.g., 1 mm, 1.1 mm, 1.2 mm, 1.3 mm, 1.4 mm, 1.5 mm, 1.6 mm, 1.7 mm, 1.8 mm, 1.9 mm or 2 mm above the corneal limbus. The shunt is then deployed into the eye from the deployment device, and the portion of the deployment device is withdrawn from the eye. Shunt implantation methods above or below the corneal limbus are preferably coupled with the step of loosening the deployment device from the surrounding eye tissue before or after deploying the shunt into the eye, as previously described.
Preferably, some methods are conducted using an ab interno approach by inserting a portion of a deployment device comprising an intraocular shunt through the cornea, across the anterior chamber, through the sclera and into an aqueous humor drainage structure such as the intra-Tenon's space, the subconjunctival space, the episcleral vein, the suprachoroidal space or Schlemm's canal. Such an approach is contrasted with an ab externo approach, which may also be used, and which involves inserting the portion of the deployment device comprising an intraocular shunt from the outside of the eye through the conjunctiva and inward through the sclera to reach a drainage structure such as Schlemm's canal. Although, some methods may be conducted using an ab externo approach.
In other certain embodiments, some methods are conducted without the use of an optical apparatus, particularly an optical apparatus that directly contacts the eye, such as a goniolens. In yet other certain embodiments, some methods are conducted using an optical apparatus that does not directly contact the eye, such as an ophthalmic microscope.
In a particular embodiment, some methods are reversible. That is, intraocular shunts that are implanted into the eye in accordance with some methods can be removed from the eye and a second shunt can be implanted in the eye.
Deployment of an intraocular shunt into the eye in accordance with some methods results in the formation of a passage that directs aqueous humor fluid flow from an area of high pressure in the eye, typically the anterior chamber, to an area of lower pressure within the eye, such as the intra-Tenon's space, the subconjunctival space, the episcleral vein, the suprachoroidal space or Schlemm's canal. Alternatively, the shunt is deployed in accordance with some methods such that it form a passage that directs aqueous humor fluid flow from an area of high pressure, such as the anterior chamber, to an area of lower pressure within the head, such as the subarachnoid space. In a preferred embodiment, deployment of an intraocular shunt in accordance with some methods results in the formation of a passage that directs aqueous humor fluid flow from the anterior chamber of the eye to the intra-Tenon's space.
The present inventions generally relate to methods for deploying intraocular shunts into the subconjunctival space the eye while avoiding or minimizing contact with the conjunctiva. In particular, the present inventions provide methods for deploying an intraocular shunt into the eye such that the shunt forms a drainage pathway from the anterior chamber of the eye to the region of the eye that is bound between the sclera and Tenon's capsule, referred to herein as the intra-Tenon's space. Deployment of an intraocular shunt such that the shunt inlet (i.e., the portion of the shunt that receives fluid from an anterior chamber of the eye) terminates in the anterior chamber and the shunt outlet (i.e., the portion of the shunt that directs fluid to the intra-Tenon's space) terminates in the intra-Tenon's space safeguards the integrity of the conjunctiva to allow subconjunctival drainage pathways to successfully form.
Some methods involve inserting into the eye a hollow shaft that is configured to hold an intraocular shunt, deploying the shunt from the shaft such that the shunt forms a passage from the anterior chamber to the intra-Tenon's space, and withdrawing the hollow shaft from the eye. The hollow shaft may hold the shunt within the interior of hollow shaft. Alternatively, the hollow shaft may hold the shunt on an outer surface of the shaft. In certain embodiments, some methods involve the use of a hollow shaft configured to hold an intraocular shunt, as previously described, wherein a portion of the hollow shaft extends linearly along a longitudinal axis and at least one other portion of the shaft extends off the longitudinal axis, to insert and deploy the intraocular shunt into the eye such that the shunt forms a passage from the anterior chamber to the intra-Tenon's space.
Optionally, an aqueous fluid is injected into the eye simultaneously with or prior to the insertion and deployment steps of some methods. For example, an aqueous solution may be injected below Tenon's capsule to balloon the capsule away from the sclera and allow positioning of the intraocular shunt in the intra-Tenon's space.
In certain aspects, the present inventions generally provide shunts composed of a material that has an elasticity modulus that is compatible with an elasticity modulus of tissue surrounding the shunt. In this manner, some embodiments of the shunt are flexibility matched with the surrounding tissue, and thus will remain in place after implantation without the need for any type of anchor that interacts with the surrounding tissue. Consequently, some embodiments of the shunt will maintain fluid flow away for an anterior chamber of the eye after implantation without causing irritation or inflammation to the tissue surrounding the eye.
Although discussed in the context of the eye, the elasticity modulus of the shunt may be matched to the elasticity modulus of any tissue. Thus, some embodiments of the shunt may be used to drain fluid from any organ. In particular embodiments, the organ is an eye. Some embodiments of the shunt may define a flow path from an area of high pressure in the eye (e.g., an anterior chamber) to an area of lower pressure in the eye (e.g., intra-Tenon's space, the subconjunctival space, the episcleral vein, the suprachoroidal space, and Schlemm's canal).
In other aspects, the present inventions generally provide shunts in which a portion of the shunt is composed of a flexible material that is reactive to pressure, i.e., an inner diameter of the shunt fluctuates depending upon the pressures exerted on that portion of the shunt. Thus, the flexible portion of the shunt acts as a valve that regulates fluid flow through the shunt. After implantation, intraocular shunts have pressure exerted upon them by tissues surrounding the shunt (e.g., scleral tissue) and pressure exerted upon them by aqueous humor flowing through the shunt. When the pressure exerted on the flexible portion of the shunt by the surrounding tissue is greater than the pressure exerted on the flexible portion of the shunt by the fluid flowing through the shunt, the flexible portion decreases in diameter, restricting flow through the shunt. The restricted flow results in aqueous humor leaving the anterior chamber at a reduced rate.
When the pressure exerted on the flexible portion of the shunt by the fluid flowing through the shunt is greater than the pressure exerted on the flexible portion of the shunt by the surrounding tissue, the flexible portion increases in diameter, increasing flow through the shunt. The increased flow results in aqueous humor leaving the anterior chamber at an increased rate.
The flexible portion of the shunt may be any portion of the shunt. In certain embodiments, the flexible portion is a distal portion of the shunt. In certain embodiments, the entire shunt is composed of the flexible material.
Other aspects of the present inventions generally provide multi-port shunts. Such shunts reduce probability of the shunt clogging after implantation because fluid can enter or exit the shunt even if one or more ports of the shunt become clogged with particulate. In certain embodiments, the shunt includes a hollow body defining a flow path and more than two ports, in which the body is configured such that a proximal portion receives fluid from the anterior chamber of an eye and a distal portion directs the fluid to a location of lower pressure with respect to the anterior chamber.
The shunt may have many different configurations. In certain embodiments, the proximal portion of the shunt (i.e., the portion disposed within the anterior chamber of the eye) includes more than one port and the distal portion of the shunt (i.e., the portion that is located in an area of lower pressure with respect to the anterior chamber such as intra-Tenon's space, the subconjunctival space, the episcleral vein, the suprachoroidal space, or Schlemm's canal) includes a single port. In other embodiments, the proximal portion includes a single port and the distal portion includes more than one port. In still other embodiments, the proximal and the distal portions include more than one port.
The ports may be positioned in various different orientations and along various different portions of the shunt. In certain embodiments, at least one of the ports is oriented at an angle to the length of the body. In certain embodiments, at least one of the ports is oriented 90° to the length of the body.
The ports may have the same or different inner diameters. In certain embodiments, at least one of the ports has an inner diameter that is different from the inner diameters of the other ports.
Other aspects of the present inventions generally provide shunts with overflow ports. Those shunts are configured such that the overflow port remains closed until there is a pressure build-up within the shunt sufficient to force open the overflow port. Such pressure build-up typically results from particulate partially or fully clogging an entry or an exit port of the shunt. Such shunts reduce probability of the shunt clogging after implantation because fluid can enter or exit the shunt by the overflow port even if one port of the shunt becomes clogged with particulate.
In certain embodiments, the shunt includes a hollow body defining an inlet configured to receive fluid from an anterior chamber of the eye and an outlet configured to direct the fluid to a location of lower pressure with respect to the anterior chamber, the body further including at least one slit. The slit may be located at any place along the body of the shunt. In certain embodiments, the slit is located in proximity to the inlet. In other embodiments, the slit is located in proximity to the outlet. In certain embodiments, there is a slit in proximity to both the inlet and the outlet of the shunt.
In certain embodiments, the slit has a width that is substantially the same or less than an inner diameter of the inlet. In other embodiments, the slit has a width that is substantially the same or less than an inner diameter of the outlet. Generally, the slit does not direct the fluid unless the outlet is obstructed. However, the shunt may be configured such that the slit does direct at least some of the fluid even if the inlet or outlet is not obstructed.
In other aspects, the present inventions generally provide a shunt having a variable inner diameter. In particular embodiments, the diameter increases from inlet to outlet of the shunt. By having a variable inner diameter that increases from inlet to outlet, a pressure gradient is produced and particulate that may otherwise clog the inlet of the shunt is forced through the inlet due to the pressure gradient. Further, the particulate will flow out of the shunt because the diameter only increases after the inlet.
In certain embodiments, the shunt includes a hollow body defining a flow path and having an inlet configured to receive fluid from an anterior chamber of an eye and an outlet configured to direct the fluid to a location of lower pressure with respect to the anterior chamber, in which the body further includes a variable inner diameter that increases along the length of the body from the inlet to the outlet. In certain embodiments, the inner diameter continuously increases along the length of the body. In other embodiments, the inner diameter remains constant along portions of the length of the body. Exemplary locations of lower pressure include the intra-Tenon's space, the subconjunctival space, the episcleral vein, the subarachnoid space, and Schlemm's canal.
In certain embodiments, some embodiments of the shunt may be coated or impregnated with at least one pharmaceutical and/or biological agent or a combination thereof. The pharmaceutical and/or biological agent may coat or impregnate an entire exterior of the shunt, an entire interior of the shunt, or both. Alternatively, the pharmaceutical and/or biological agent may coat and/or impregnate a portion of an exterior of the shunt, a portion of an interior of the shunt, or both. Methods of coating and/or impregnating an intraocular shunt with a pharmaceutical and/or biological agent are known in the art. See, for example, Darouiche (U.S. Pat. Nos. 7,790,183; 6,719,991; 6,558,686; 6,162,487; 5,902,283; 5,853,745; and 5,624,704) and Yu et al. (U.S. Pat. Pub. No. 2008/0108933). The content of each of these references is incorporated by reference herein its entirety.
In certain embodiments, the exterior portion of the shunt that resides in the anterior chamber after implantation (e.g., about 1 mm of the proximal end of the shunt) is coated and/or impregnated with the pharmaceutical or biological agent. In other embodiments, the exterior of the shunt that resides in the scleral tissue after implantation of the shunt is coated and/or impregnated with the pharmaceutical or biological agent. In other embodiments, the exterior portion of the shunt that resides in the area of lower pressure (e.g., the intra-Tenon's space or the subconjunctival space) after implantation is coated and/or impregnated with the pharmaceutical or biological agent. In embodiments in which the pharmaceutical or biological agent coats and/or impregnates the interior of the shunt, the agent may be flushed through the shunt and into the area of lower pressure (e.g., the intra-Tenon's space or the subconjunctival space).
Any pharmaceutical and/or biological agent or combination thereof may be used with some embodiments of the shunt. The pharmaceutical and/or biological agent may be released over a short period of time (e.g., seconds) or may be released over longer periods of time (e.g., days, weeks, months, or even years). Exemplary agents include anti-mitotic pharmaceuticals such as Mitomycin-C or 5-Fluorouracil, anti-VEGF (such as Lucintes, Macugen, Avastin, VEGF or steroids).
The shunts discussed above and herein are described relative to the eye and, more particularly, in the context of treating glaucoma and solving the above identified problems relating to intraocular shunts. Nonetheless, it will be appreciated that shunts described herein may find application in any treatment of a body organ requiring drainage of a fluid from the organ and are not limited to the eye.
The present inventions provide devices and methods for self-guided implantation of soft gel tissue compliant intraocular shunts in the suprachoroidal space. Shunt placement in the suprachoroidal space avoids contact with the conjunctiva, thus safeguarding the integrity of the conjunctiva. Implanting shunts made of soft, tissue compliant material avoid the creation of a cyclodialysis cleft and reduces or eliminates the risk of hypotony and related side effects.
Some embodiments of the device accomplish self-guided shunt deployment in the suprachoroidal space by having a flexible hollow shaft with a bend that biases the shunt to follow the scleral spur as it is deployed from the shaft. The hollow shaft is pre-bent to match the angle or arc of the sclera. In a pre-deployment configuration, the shaft is disposed within the device. The rigidity of the device holds the hollow shaft in a straight configuration. Upon its exposure from the device, the hollow shaft reverts to its pre-bent configuration. Such a pre-bend allows the hollow shaft to follow the scleral spur down along the sclera in a self-guided manner to the suprachoroidal space. Additionally, the flexibility of the hollow shaft allows it to continually bend and flex in response to the anatomy as the hollow shaft advances from the device. Once properly positioned, the shunt is deployed from the shaft. The bend in the shaft self-guides the shunt along the scleral spur of the eye as the shaft is retracted into the device and the shunt is deployed from the shaft.
In certain aspects, some embodiments of the device also include a housing and a deployment mechanism at least partially disposed in the housing. In certain embodiments, the hollow shaft is coupled to the deployment mechanism. The housing may include two components, a proximal portion and a distal portion. The components are configured such that the distal portion is movable within the proximal portion. In certain embodiments, the distal portion of the housing includes a stiff sleeve and the shaft is movably disposed within the sleeve. In other embodiments, the distal portion is without a stiff outer sleeve. As previously described, the shaft is flexible and pre-bent to match an angle of the sclera. In certain embodiments, the distal end of the hollow shaft includes a sharp tip to assist in piercing the sclera. In certain embodiments, the hollow shaft is a flexible needle.
In other embodiments, a distal end of the sleeve further includes a protrusion. The protrusion may be formed integrally with the distal end of the sleeve or may be connected to a distal end of the sleeve. The protrusion may surround the distal end of the sleeve, or the protrusion may extend around only a portion of the sleeve. In certain embodiments, the protrusion is a collar that surrounds the distal end of the sleeve. In other embodiments, the protrusion includes a flat bottom portion and an angled top portion. In particular embodiments, the angle of the top portion is substantially identical to an anterior chamber angle of an eye.
Other aspects of some embodiments provide for methods of using the above described devices for inserting a intraocular shunt into the suprachoroidal space of an eye. Such methods involve inserting the above device into an eye and deploying a shunt from the device within the eye such that a proximal portion of the shunt receives fluid from an anterior chamber of an eye and a distal portion of the shunt directs the fluid to the suprachoroidal space. Some methods may also involve injecting a drug into the suprachoroidal space prior to deploying the shunt from the device. Exemplary drugs include drug is a BSS/steroids or antifibrotic agents.
The present inventions generally relate to methods for treating closed angle glaucoma that involve using a deployment device that is configured to both re-open a partially or completely closed anterior chamber angle and deploy an intraocular shunt. In certain aspects, some methods involve inserting into an eye a deployment device configured to hold an intraocular shunt, using the device to re-open an at least partially closed anterior chamber angle of an eye, and deploying the shunt from the device.
In conditions of glaucoma, the pressure of the aqueous humor in the eye (anterior chamber) increases and this resultant increase of pressure can cause damage to the vascular system at the back of the eye and especially to the optic nerve. The treatment of glaucoma and other diseases that lead to elevated pressure in the anterior chamber involves relieving pressure within the anterior chamber to a normal level.
Glaucoma filtration surgery is a surgical procedure typically used to treat glaucoma. The procedure involves placing a shunt in the eye to relieve intraocular pressure by creating a pathway for draining aqueous humor from the anterior chamber of the eye. The shunt is typically positioned in the eye such that it creates a fluid-flow pathway between the anterior chamber of the eye and a region of lower pressure. Various structures and/or regions of the eye having lower pressure that have been targeted for aqueous humor drainage include Schlemm's canal, the subconjunctival space, the episcleral vein, the suprachoroidal space, or the subarachnoid space. Methods of implanting intraocular shunts are known in the art. Shunts may be implanted using an ab externo approach (entering through the conjunctiva and inwards through the sclera) or an ab interno approach (entering through the cornea, across the anterior chamber, and through the trabecular meshwork and sclera).
Ab interno approaches for implanting an intraocular shunts have been described and may vary depending on the structure targeted for aqueous humor drainage. For example, ab interno approaches for implanting an intraocular shunt into the subconjunctival space are shown in Yu et al. (U.S. Pat. No. 6,544,249 and U.S. Pat. Pub. No. 2008/0108933) and Prywes (U.S. Pat. No. 6,007,511), the contents of each of which are incorporated by reference herein in its entirety. Briefly and with reference to
Previously proposed deployment devices for implanting an intraocular shunt into the eye, whether using an ab externo procedure or an ab interno procedure, typically include a plunger-type mechanism for deploying the shunt into the eye, such as the deployment device illustrated in
However, complications can arise when using such deployment devices due to the frictional interaction between the deployment device and the surrounding eye tissue that results upon insertion of the deployment device into the eye and/or deployment of the intraocular shunt into the eye from the deployment device. Moderate to severe eye trauma can occur, beyond any trauma due to insertion of the deployment device, if the portion of the deployment device inserted into the eye is not loosened before or after deployment of the intraocular shunt from the device and prior to withdrawing the portion of the deployment device from the eye.
The present inventions provide improved methods for implanting an intraocular shunt into the eye while avoiding or at least minimizing the amount of trauma to the eye that is typically involved with shunt implantation procedures. According to some methods, any frictional resistance between the deployment device and surrounding eye tissue that is created upon insertion of a portion of a deployment device in the eye is resolved by loosening the portion of the deployment device from the surrounding eye tissue before or after deployment of the intraocular shunt from the device and prior to withdrawing the portion of the deployment device from the eye. The methods can be used in conjunction with any known shunt deployment device, and in particular, any deployment device that includes a portion for holding an intraocular shunt or is coupled to a hollow shaft which is configured to hold an intraocular shunt.
Preferably, at least a portion of the deployment device is rotated before the shunt is deployed into the eye from the deployment device, in order to loosen the portion of the device inserted into the eye from the surrounding eye tissue prior to withdrawing the deployment device from the eye. Rotation may be clockwise or counterclockwise, and may be performed manually or in an automated manner. Rotation of only a distal portion of the deployment device may be sufficient to loosen the portion of the deployment device in the eye from the surrounding eye tissue, depending on the configuration of the device. Alternatively, rotation of the entire deployment device serves to loosen the portion of the deployment device in the eye from the surrounding eye tissue. Rotation of the deployment device, or a portion thereof, causes the portion of the deployment device that is inserted into the eye to also rotate, thereby loosening the portion of the deployment device in the eye form the surrounding eye tissue. Examples of surrounding eye tissue include but are not limited to the scleral tissue and the trabecular meshwork.
The deployment device, or a portion thereof, is rotated clockwise or counterclockwise about the longitudinal axis of the deployment device itself. The rotation about the longitudinal axis is preferably between 1° and 360°, or any specific value within said range, e.g., 1°, 3°, 5°, 10°, 15°, 30°, 45°, 60°, 75°, 90°, 105°, 120°, 135°, 150° 165°, 180°, 195°, 210°, 225°, 240°, 255°, 270°, 285°, 300°, 315°, 330°, 345° or 360°.
As previously stated, some methods can be used in conjunction with any shunt deployment device.
In some embodiments, the hollow shaft for use in accordance with some methods is straight along the entire length of the shaft. Alternatively, a portion of the hollow shaft extends linearly along a longitudinal axis and at least one other portion of the shaft extends off the longitudinal axis. For example, the hollow shaft may have a bend in the distal portion of the shaft, a U-shape, or an arcuate or V-shape in at least a portion of the shaft. Examples of such hollow shafts suitable for use with some methods include but are not limited to the hollow shafts depicted in
Preferably, some methods are conducted by making an incision in the eye prior to insertion of the deployment device configured to hold the intraocular shunt. Although in particular embodiments, some methods may be conducted without making an incision in the eye prior to insertion of the deployment device configured to hold the intraocular shunt. In certain embodiments, the distal end of the deployment device (i.e. the portion that is inserted into the eye) has a sharpened point or tip. For example, the distal end of the deployment device includes or is coupled to a needle configured to hold an intraocular shunt. Needles that are configured to hold an intraocular shunt are commercially available from Terumo Medical Corp. (Elkington Md.). In a particular embodiment, the distal end of the deployment device is coupled to a needle having a hollow interior and a beveled tip, and the intraocular shunt is held within the hollow interior of the needle. In another particular embodiment, the distal end of the deployment device is coupled to a needle having a hollow interior and a triple ground point or tip.
Some methods are preferably conducted without needing to remove an anatomical portion or feature of the eye, including but not limited to the trabecular meshwork, the iris, the cornea, or aqueous humor. Some methods are also preferably conducting without inducing substantial ocular inflammation, such as subconjunctival blebbing or endophthalmitis. Such methods are preferably achieved using an ab interno approach by inserting the deployment device comprising the intraocular shunt through the cornea, across the anterior chamber, through the trabecular meshwork and sclera and into a drainage structure such as Schlemm's canal, the subconjunctival space, the episcleral vein, the suprachoroidal space, the intra-Tenon's space or the subarachnoid space. However, some methods may be conducted using an ab externo approach.
When some methods are conducted using an ab interno approach, the deployment device is preferably inserted into the eye at an angle above or below the corneal limbus, inserted in contrast with entering through the corneal limbus. Preferably, the deployment device is inserted above the corneal limbus. For example, the deployment device is inserted approximately 0.25 to 3.0 mm, preferably approximately 0.5 to 2.5 mm, more preferably approximately 1.0 mm to 2.0 mm above the corneal limbus, or any specific value within said ranges, e.g., approximately 1.0 mm, approximately 1.1 mm, approximately 1.2 mm, approximately 1.3 mm, approximately 1.4 mm, approximately 1.5 mm, approximately 1.6 mm, approximately 1.7 mm, approximately 1.8 mm, approximately 1.9 mm or approximately 2.0 mm above the corneal limbus.
Entering at an angle above or below the corneal limbus is advantageous for placing the shunt farther from the limbus at the exit site. It also adds more distance between the shunt and the iris.
Without intending to be bound by any theory, placement of the shunt farther from the limbus at the exit site, as provided by an angle of entry above the limbus, is believed to provide access to more lymphatic channels for drainage of aqueous humor, such as the episcleral lymphatic network, in addition to the conjunctival lymphatic system. A higher angle of entry also results in flatter placement in the intra-Tenon's space so that there is less bending of the shunt, less pressure on Tenon's capsule, and subsequently less erosion pressure on the conjunctiva via Tenon's capsule.
For example, as shown in
Deployment of an intraocular shunt in the eye in accordance with some methods results in the formation of a passage that directs fluid flow from an area of high pressure in the eye, typically the anterior chamber, to an area of lower pressure within the eye or within the head, to relieve or reduce intraocular pressure. Areas of lower pressure within the eye that are suited for aqueous humor drainage include but are not limited to the intra-Tenon's space, the subconjunctival space, the episceleral vein, the suprachoroidal space and Schlemm's canal. Alternatively, the subarachnoid space may provide a drainage outlet for aqueous humor from the anterior chamber. Preferably, deployment of the shunt results in the formation of a passage for directing fluid flow between the anterior chamber and the intra-Tenon's space.
Deployment of an intraocular shunt such that the inlet (i.e., the portion of the shunt that receives fluid from an anterior chamber of the eye) terminates in the anterior chamber and the outlet (i.e., the portion of the shunt that directs fluid to the intra-Tenon's space) terminates in the intra-Tenon's space provides superior benefits over deployment generally in the subconjunctival space. Deployment of the shunt outlet in the intra-Tenon's space safeguards the integrity of the conjunctiva to allow subconjunctival drainage pathways to successfully form. See, for example, Yu et al., Progress in Retinal and Eye Research, 28: 303-328 (2009)). Additionally, drainage into the intra-Tenon's space provides access to more lymphatic channels than just the conjunctival lymphatic system, such as the episcleral lymphatic network. Moreover, deployment of an intraocular shunt such that the outlet terminates in the intra-Tenon's space avoids having to pierce Tenon's capsule which can otherwise cause complications during glaucoma filtration surgery due to its tough and fibrous nature.
Methods for Intra-Tenon's Shunt Placement
Some methods involve inserting into the eye a hollow shaft configured to hold an intraocular shunt. In certain embodiments, the hollow shaft is a component of a deployment device that may deploy the intraocular shunt. The shunt is then deployed from the shaft into the eye such that the shunt forms a passage from the anterior chamber to the intra-Tenon's space. The hollow shaft is then withdrawn from the eye.
Referring to
Numerous techniques may be employed to ensure that after piercing the sclera 105, the hollow shaft 106 does not pierce Tenon's capsule 107. In certain embodiments, some methods involve the use of a hollow shaft 106, in which a portion of the hollow shaft extends linearly along a longitudinal axis and at least one other portion of the shaft extends off the longitudinal axis. For example, the hollow shaft 106 may have a bend in the distal portion of the shaft, a U-shape, or an arcuate or V-shape in at least a portion of the shaft. Examples of such hollow shafts 106 suitable for use with some methods include but are not limited to the hollow shafts 106 depicted in
In other embodiments, a straight hollow shaft 106 having a beveled tip is employed. The angle of the beveled tip of the hollow shaft is configured such that after piercing the sclera 105, the hollow shaft 106 does not pierce Tenon's capsule 107. In these embodiments, the shaft 106 is inserted into the eye 102 and through the sclera 105 at an angle such that the bevel of the tip is parallel to Tenon's capsule 107, thereby pushing Tenon's capsule 107 away from the sclera 105, rather than penetrating Tenon's capsule 107, and allowing for deployment of a distal portion of the shunt 101 into the intra-Tenon's space 108.
Once a distal portion of the hollow shaft 106 is within the intra-Tenon's space 108, at least a portion of the device is rotated, thereby reducing the friction between the portion of the device that is in contact with the scleral tissue and the scleral tissue itself. Reduction in friction allows for deployment of the shunt from the device and then removal of the device from the eye without disturbing the tissue of the eye. After rotating the device, the shunt 101 is then deployed from the shaft 106 of the deployment device 100, producing a conduit between the anterior chamber 104 and the intra-Tenon's space 108 to allow aqueous humor to drain from the anterior chamber 104 (See
In another embodiment, some methods further involves injecting an aqueous solution into the eye below Tenon's capsule in order to balloon the capsule away from the sclera. The increase in intra-Tenon's space caused by the ballooning of Tenon's capsule is helpful for positioning of the outlet of the shunt in the intra-Tenon's space. The solution is injected prior to the shaft piercing the sclera and entering the intra-Tenon's space. Suitable aqueous solutions include but are not limited to Dulbecco's Phosphate Buffered Saline (DPBS), Hank's Balanced Salt Solution (HBSS), Phosphate-Buffered Saline (PBS), Earle's Balanced Salt Solution (EBSS), or other balanced salt solutions known in the art. In some embodiments, some methods involve injecting a viscoelastic fluid into the eye. Preferably, some methods are conducted without the use of a viscoelastic fluid. Some methods can be conducted using any shunt deployment device known in the art. Examples of deployment devices that are suitable for use with some methods include but are not limited to the devices described in U.S. Pat. Nos. 6,007,511, 6,544,249, and U.S. Pat. Pub. No. US2008/0108933, the contents of each of which are hereby incorporated by reference in their entireties.
In certain embodiments, to ensure proper positioning and functioning of the intraocular shunt, the depth of penetration through the sclera is important when conducting some methods. In one embodiment, the distal tip of the hollow shaft pierces the sclera without coring, removing or causing major tissue distortion of the surrounding eye tissue. The shunt is then deployed from the shaft. Preferably, a distal portion of the hollow shaft (as opposed to the distal tip) completely penetrates the sclera before the shunt is deployed from the hollow shaft. In certain embodiments, the hollow shaft is a flat bevel needle, such as a needle having a triple-ground point. The tip bevel first pierces through the sclera making a horizontal slit. In a preferred embodiment of some methods, the needle is advanced even further such that the entire flat bevel penetrates through the sclera, as shown in
Some methods may be conducted using any commercially available shunts, such as the Optonol Ex-PRESS mini Glaucoma shunt, and the Solx DeepLight Gold Micro-Shunt. However, some methods are preferably conducted using the intraocular shunts of some embodiments, as described herein.
Intraocular Shunts
The present inventions also provide intraocular shunts that are configured to form a drainage pathway from the anterior chamber of the eye to the intra-Tenon's space. In particular, the intraocular some embodiments of the shunt have a length that is sufficient to form a drainage pathway from the anterior chamber of the eye to the intra-Tenon's space. The length of the shunt is important in achieving placement specifically in the intra-Tenon's space. A shunt that is too long will extend beyond the intra-Tenon's space and irritate the conjunctiva, which can cause the filtration procedure to fail, as previously described. A shunt that is too short will not provide sufficient access to drainage pathways such as the episcleral lymphatic system or the conjunctival lymphatic system.
Some embodiments of the shunt may be any length that allows for drainage of aqueous humor from an anterior chamber of an eye to the intra-tenon's space. Exemplary shunts range in length from approximately 0.5 mm to approximately 20 mm or between approximately 4 mm to approximately 16 mm, or any specific value within said ranges. In certain embodiments, the length of the shunt is between approximately 6 to 8 mm, or any specific value within said range, e.g., 6.0 mm, 6.1 mm, 6.2 mm, 6.3 mm, 6.4 mm, 6.5 mm, 6.6 mm, 6.7 mm, 6.8 mm, 6.9 mm, 7 mm, 7.1 mm, 7.2 mm, 7.3 mm, 7.4 mm, 7.5 mm, 7.6 mm, 7.7 mm, 7.8 mm. 7.9 mm, or 8.0 mm.
The intraocular some embodiments of the shunt are particularly suitable for use in an ab interno glaucoma filtration procedure. Commercially available shunts that are currently used in ab interno filtration procedures are typically made of a hard, inflexible material such as gold, polymer, titanium, or stainless steel, and cause substantial irritation of the eye tissue, resulting in ocular inflammation such as subconjunctival blebbing or endophthalmitis. In contrast, the intraocular some embodiments of the shunt are flexible, and have an elasticity modulus that is substantially identical to the elasticity modulus of the surrounding tissue in the implant site. As such, the intraocular some embodiments of the shunt are easily bendable, do not erode or cause a tissue reaction, and do not migrate once implanted. Thus, when implanted in the eye using an ab interno procedure, such as the methods described herein, the intraocular some embodiments of the shunt do not induce substantial ocular inflammation such as subconjunctival blebbing or endophthalmitis. Additional exemplary features of the intraocular some embodiments of the shunt are discussed in further detail below.
Tissue Compatible Shunts
In certain aspects, some embodiments generally provide shunts composed of a material that has an elasticity modulus that is compatible with an elasticity modulus of tissue surrounding the shunt (e.g., tissue surrounding the suprachoroidal space). In this manner, some embodiments of the shunt are flexibility matched with the surrounding tissue, and thus will remain in place after implantation without the need for any type of anchor that interacts with the surrounding tissue. Consequently, some embodiments of the shunt will maintain fluid flow away for an anterior chamber of the eye after implantation without causing irritation or inflammation to the tissue surrounding the eye.
Elastic modulus, or modulus of elasticity, is a mathematical description of an object or substance's tendency to be deformed elastically when a force is applied to it. The elastic modulus of an object is defined as the slope of its stress-strain curve in the elastic deformation region:
where lambda (λ) is the elastic modulus; stress is the force causing the deformation divided by the area to which the force is applied; and strain is the ratio of the change caused by the stress to the original state of the object. The elasticity modulus may also be known as Young's modulus (E), which describes tensile elasticity, or the tendency of an object to deform along an axis when opposing forces are applied along that axis. Young's modulus is defined as the ratio of tensile stress to tensile strain. For further description regarding elasticity modulus and Young's modulus, see for example Gere (Mechanics of Materials, 6th Edition, 2004, Thomson), the content of which is incorporated by reference herein in its entirety.
The elasticity modulus of any tissue can be determined by one of skill in the art. See for example Samani et al. (Phys. Med. Biol. 48:2183, 2003); Erkamp et al. (Measuring The Elastic Modulus Of Small Tissue Samples, Biomedical Engineering Department and Electrical Engineering and Computer Science Department University of Michigan Ann Arbor, Mich. 48109-2125; and Institute of Mathematical Problems in Biology Russian Academy of Sciences, Pushchino, Moscow Region 142292 Russia); Chen et al. (IEEE Trans. Ultrason. Ferroelec. Freq. Control 43:191-194, 1996); Hall, (In 1996 Ultrasonics Symposium Proc., pp. 1193-1196, IEEE Cat. No. 96CH35993, IEEE, New York, 1996); and Parker (Ultrasound Med. Biol. 16:241-246, 1990), each of which provides methods of determining the elasticity modulus of body tissues. The content of each of these is incorporated by reference herein in its entirety.
The elasticity modulus of tissues of different organs is known in the art. For example, Pierscionek et al. (Br J Ophthalmol, 91:801-803, 2007) and Friberg (Experimental Eye Research, 473:429-436, 1988) show the elasticity modulus of the cornea and the sclera of the eye. The content of each of these references is incorporated by reference herein in its entirety. Chen, Hall, and Parker show the elasticity modulus of different muscles and the liver. Erkamp shows the elasticity modulus of the kidney.
Some embodiments of the shunt are composed of a material that is compatible with an elasticity modulus of tissue surrounding the shunt. In certain embodiments, the material has an elasticity modulus that is substantially identical to the elasticity modulus of the tissue surrounding the shunt. In other embodiments, the material has an elasticity modulus that is greater than the elasticity modulus of the tissue surrounding the shunt. Exemplary materials includes biocompatible polymers, such as polycarbonate, polyethylene, polyethylene terephthalate, polyimide, polystyrene, polypropylene, poly(styrene-b-isobutylene-b-styrene), or silicone rubber.
In particular embodiments, some embodiments of the shunt are composed of a material that has an elasticity modulus that is compatible with the elasticity modulus of tissue in the eye, particularly scleral tissue. In certain embodiments, compatible materials are those materials that are softer than scleral tissue or marginally harder than scleral tissue, yet soft enough to prohibit shunt migration. The elasticity modulus for anterior scleral tissue is approximately 2.9±1.4×106 N/m2, and 1.8±1.1×106 N/m2 for posterior scleral tissue. See Friberg (Experimental Eye Research, 473:429-436, 1988). An exemplary material is cross linked gelatin derived from Bovine or Porcine Collagen.
Some embodiments encompasses shunts of different shapes and different dimensions, and some embodiments of the shunt may be any shape or any dimension that may be accommodated by the eye. In certain embodiments, the intraocular shunt is of a cylindrical shape and has an outside cylindrical wall and a hollow interior. The shunt may have an inside diameter from approximately 10 μm to approximately 250 an outside diameter from diameter from approximately 100 μm to approximately 450 such as approximately 190 μm to approximately 300 and a length from approximately 0.5 mm to approximately 20 mm, such as from approximately 2 mm to approximately 10 mm.
Shunts Reactive to Pressure
In other aspects, some embodiments generally provide shunts in which a portion of the shunt is composed of a flexible material that is reactive to pressure, i.e., the diameter of the flexible portion of the shunt fluctuates depending upon the pressures exerted on that portion of the shunt.
The flexible portion 251 of the shunt 223 acts as a valve that regulates fluid flow through the shunt. The human eye produces aqueous humor at a rate of about 2 μl/min for approximately 3 ml/day. The entire aqueous volume is about 0.25 ml. When the pressure in the anterior chamber falls after surgery to about 7-8 mmHg, it is assumed the majority of the aqueous humor is exiting the eye through the implant since venous backpressure prevents any significant outflow through normal drainage structures (e.g., the trabecular meshwork).
After implantation, intraocular shunts have pressure exerted upon them by tissues surrounding the shunt (e.g., scleral tissue such as the sclera channel and the sclera exit) and pressure exerted upon them by aqueous humor flowing through the shunt. The flow through the shunt, and thus the pressure exerted by the fluid on the shunt, is calculated by the equation:
where Φ is the volumetric flow rate; V is a volume of the liquid poured (cubic meters); t is the time (seconds); v is mean fluid velocity along the length of the tube (meters/second); x is a distance in direction of flow (meters); R is the internal radius of the tube (meters); ΔP is the pressure difference between the two ends (pascals); η is the dynamic fluid viscosity (pascal-second (Pass)); and L is the total length of the tube in the x direction (meters).
When the pressure exerted on the flexible portion 230 of the shunt 226 by sclera 231 (vertical arrows) is greater than the pressure exerted on the flexible portion 230 of the shunt 226 by the fluid flowing through the shunt (horizontal arrow), the flexible portion 230 decreases in diameter, restricting flow through the shunt 226 (
When the pressure exerted on the flexible portion 230 of the shunt 226 by the fluid flowing through the shunt (horizontal arrow) is greater than the pressure exerted on the flexible portion 230 of the shunt 226 by the sclera 231 (vertical arrows), the flexible portion 230 increases in diameter, increasing flow through the shunt 226 (
Some embodiments encompasses shunts of different shapes and different dimensions, and some embodiments of the shunt may be any shape or any dimension that may be accommodated by the eye. In certain embodiments, the intraocular shunt is of a cylindrical shape and has an outside cylindrical wall and a hollow interior. The shunt may have an inside diameter from approximately 10 μm to approximately 250 μm, an outside diameter from diameter from approximately 100 μm to approximately 450 μm, such as approximately 190 μm to approximately 300 μm, and a length from approximately 0.5 mm to approximately 20 mm, such as from approximately 2 mm to approximately 10 mm.
In a particular embodiments, the shunt has a length of about 6 mm and an inner diameter of about 64 μm. With these dimensions, the pressure difference between the proximal end of the shunt that resides in the anterior chamber and the distal end of the shunt that resides outside the anterior chamber is about 4.3 mmHg. Such dimensions thus allow the implant to act as a controlled valve and protect the integrity of the anterior chamber.
It will be appreciated that different dimensioned implants may be used. For example, shunts that range in length from about 0.5 mm to about 20 mm, such as from about 2 mm to about 10 mm, and have a range in inner diameter from about 10 μm to about 100 μm allow for pressure control from approximately 0.5 mmHg to approximately 20 mmHg.
The material of the flexible portion and the thickness of the wall of the flexible portion will determine how reactive the flexible portion is to the pressures exerted upon it by the surrounding tissue and the fluid flowing through the shunt. Generally, with a certain material, the thicker the flexible portion, the less responsive the portion will be to pressure. In certain embodiments, the flexible portion is a gelatin or other similar material, and the thickness of the gelatin material forming the wall of the flexible portion ranges from about 10 μm thick to about 100 μm thick.
In a certain embodiment, the gelatin used for making the flexible portion is known as gelatin Type B from bovine skin. An exemplary gelatin is PB Leiner gelatin from bovine skin, Type B, 225 Bloom, USP. Another material that may be used in the making of the flexible portion is a gelatin Type A from porcine skin, also available from Sigma Chemical. Such gelatin is available from Sigma Chemical Company of St. Louis, Mo. under Code G-9382. Still other suitable gelatins include bovine bone gelatin, porcine bone gelatin and human-derived gelatins. In addition to gelatins, the flexible portion may be made of hydroxypropyl methylcellulose (HPMC), collagen, polylactic acid, polylglycolic acid, hyaluronic acid and glycosaminoglycans.
In certain embodiments, the gelatin is cross-linked. Cross-linking increases the inter- and intramolecular binding of the gelatin substrate. Any method for cross-linking the gelatin may be used. In a particular embodiment, the formed gelatin is treated with a solution of a cross-linking agent such as, but not limited to, glutaraldehyde. Other suitable compounds for cross-linking include 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC). Cross-linking by radiation, such as gamma or electron beam (e-beam) may be alternatively employed.
In one embodiment, the gelatin is contacted with a solution of approximately 25% glutaraldehyde for a selected period of time. One suitable form of glutaraldehyde is a grade 1G5882 glutaraldehyde available from Sigma Aldridge Company of Germany, although other glutaraldehyde solutions may also be used. The pH of the glutaraldehyde solution should be in the range of 7 to 7.8 and, more particularly, 7.35-7.44 and typically approximately 7.4+/−0.01. If necessary, the pH may be adjusted by adding a suitable amount of a base such as sodium hydroxide as needed.
Methods for forming the flexible portion of the shunt are shown for example in Yu et al. (U.S. Pat. Pub. No. 2008/0108933), the content of which is incorporated by reference herein in its entirety. In an exemplary protocol, the flexible portion may be made by dipping a core or substrate such as a wire of a suitable diameter in a solution of gelatin. The gelatin solution is typically prepared by dissolving a gelatin powder in de-ionized water or sterile water for injection and placing the dissolved gelatin in a water bath at a temperature of approximately 55° C. with thorough mixing to ensure complete dissolution of the gelatin. In one embodiment, the ratio of solid gelatin to water is approximately 10% to 50% gelatin by weight to 50% to 90% by weight of water. In an embodiment, the gelatin solution includes approximately 40% by weight, gelatin dissolved in water. The resulting gelatin solution should be devoid of air bubbles and has a viscosity that is between approximately 200-500 cp and more particularly between approximately 260 and 410 cp (centipoise).
Once the gelatin solution has been prepared, in accordance with the method described above, supporting structures such as wires having a selected diameter are dipped into the solution to form the flexible portion. Stainless steel wires coated with a biocompatible, lubricious material such as polytetrafluoroethylene (Teflon) are preferred.
Typically, the wires are gently lowered into a container of the gelatin solution and then slowly withdrawn. The rate of movement is selected to control the thickness of the coat. In addition, it is preferred that a the tube be removed at a constant rate in order to provide the desired coating. To ensure that the gelatin is spread evenly over the surface of the wire, in one embodiment, the wires may be rotated in a stream of cool air which helps to set the gelatin solution and affix film onto the wire. Dipping and withdrawing the wire supports may be repeated several times to further ensure even coating of the gelatin. Once the wires have been sufficiently coated with gelatin, the resulting gelatin films on the wire may be dried at room temperature for at least 1 hour, and more preferably, approximately 10 to 24 hours. Apparatus for forming gelatin tubes are described in Yu et al. (U.S. Pat. Pub. No. 2008/0108933).
Once dried, the formed flexible portions may be treated with a cross-linking agent. In one embodiment, the formed flexible portion may be cross-linked by dipping the wire (with film thereon) into the 25% glutaraldehyde solution, at pH of approximately 7.0-7.8 and more preferably approximately 7.35-7.44 at room temperature for at least 4 hours and preferably between approximately 10 to 36 hours, depending on the degree of cross-linking desired. In one embodiment, the formed flexible portion is contacted with a cross-linking agent such as gluteraldehyde for at least approximately 16 hours. Cross-linking can also be accelerated when it is performed a high temperatures. It is believed that the degree of cross-linking is proportional to the bioabsorption time of the shunt once implanted. In general, the more cross-linking, the longer the survival of the shunt in the body.
The residual glutaraldehyde or other cross-linking agent is removed from the formed flexible portion by soaking the tubes in a volume of sterile water for injection. The water may optionally be replaced at regular intervals, circulated or re-circulated to accelerate diffusion of the unbound glutaraldehyde from the tube. The tubes are washed for a period of a few hours to a period of a few months with the ideal time being 3-14 days. The now cross-linked gelatin tubes may then be dried (cured) at ambient temperature for a selected period of time. It has been observed that a drying period of approximately 48-96 hours and more typically 3 days (i.e., 72 hours) may be preferred for the formation of the cross-linked gelatin tubes.
Where a cross-linking agent is used, it may be desirable to include a quenching agent in the method of making the flexible portion. Quenching agents remove unbound molecules of the cross-linking agent from the formed flexible portion. In certain cases, removing the cross-linking agent may reduce the potential toxicity to a patient if too much of the cross-linking agent is released from the flexible portion. In certain embodiments, the formed flexible portion is contacted with the quenching agent after the cross-linking treatment and, may be included with the washing/rinsing solution. Examples of quenching agents include glycine or sodium borohydride.
The formed flexible portion may be further coated or impregnated with biologics and/or pharmaceuticals, as discussed herein.
After the requisite drying period, the formed and cross-linked flexible portion is removed from the underlying supports or wires. In one embodiment, wire tubes may be cut at two ends and the formed gelatin flexible portion slowly removed from the wire support. In another embodiment, wires with gelatin film thereon, may be pushed off using a plunger or tube to remove the formed gelatin flexible portion.
Multi-Port Shunts
Other aspects of some embodiments generally provide multi-port shunts. Such shunts reduce probability of the shunt clogging after implantation because fluid can enter or exit the shunt even if one or more ports of the shunt become clogged with particulate. In certain embodiments, the shunt includes a hollow body defining a flow path and more than two ports, in which the body is configured such that a proximal portion receives fluid from the anterior chamber of an eye and a distal portion directs the fluid to a location of lower pressure with respect to the anterior chamber. Exemplary areas of lower pressure include intra-Tenon's space, the subconjunctival space, the episcleral vein, the suprachoroidal space, Schlemm's canal, or drainage structures associated with the intra-scleral space. Another exemplary area of lower pressure to which fluid may be drained is the subarachnoid space.
The shunt may have many different configurations.
The ports may be positioned in various different orientations and along various different portions of the shunt. In certain embodiments, at least one of the ports is oriented at an angle to the length of the body. In certain embodiments, at least one of the ports is oriented 90° to the length of the body. See for example
The ports may have the same or different inner diameters. In certain embodiments, at least one of the ports has an inner diameter that is different from the inner diameters of the other ports.
Some embodiments encompasses shunts of different shapes and different dimensions, and some embodiments of the shunt may be any shape or any dimension that may be accommodated by the eye. In certain embodiments, the intraocular shunt is of a cylindrical shape and has an outside cylindrical wall and a hollow interior. The shunt may have an inside diameter from approximately 10 μm to approximately 250 an outside diameter from approximately 190 μm to approximately 300 and a length from approximately 0.5 mm to approximately 20 mm. Some embodiments of the shunt may be made from any biocompatible material. An exemplary material is gelatin. Methods of making shunts composed of gelatin are described above.
Shunts with Overflow Ports
Other aspects of some embodiments generally provide shunts with overflow ports. Those shunts are configured such that the overflow port remains partially or completely closed until there is a pressure build-up within the shunt sufficient to force open the overflow port. Such pressure build-up typically results from particulate partially or fully clogging an entry or an exit port of the shunt. Such shunts reduce probability of the shunt clogging after implantation because fluid can enter or exit the shunt by the overflow port even if one port of the shunt becomes clogged with particulate.
In certain embodiments, the shunt includes a hollow body defining an inlet configured to receive fluid from an anterior chamber of an eye and an outlet configured to direct the fluid to the intra-Tenon's or intrascleral space, or other areas of lower pressure disclosed herein, the body further including at least one slit. The slit may be located at any place along the body of the shunt.
While
In certain embodiments, the slit may be at the proximal or the distal end of the shunt, producing a split in the proximal or the distal end of the implant.
In certain embodiments, the slit has a width that is substantially the same or less than an inner diameter of the inlet. In other embodiments, the slit has a width that is substantially the same or less than an inner diameter of the outlet. In certain embodiments, the slit has a length that ranges from about 0.05 mm to about 2 mm, and a width that ranges from about 10 μm to about 200 μm. Generally, the slit does not direct the fluid unless the outlet is obstructed. However, the shunt may be configured such that the slit does direct at least some of the fluid even if the inlet or outlet is not obstructed.
Some embodiments encompasses shunts of different shapes and different dimensions, and some embodiments of the shunt may be any shape or any dimension that may be accommodated by the eye. In certain embodiments, the intraocular shunt is of a cylindrical shape and has an outside cylindrical wall and a hollow interior. The shunt may have an inside diameter from approximately 10 μm to approximately 250 μm, an outside diameter from diameter from approximately 100 μm to approximately 450 μm, such as approximately 190 μm to approximately 300 μm, and a length from approximately 0.5 mm to approximately 20 mm, such as from approximately 2 mm to approximately 10 mm. Some embodiments of the shunt may be made from any biocompatible material. An exemplary material is gelatin. Methods of making shunts composed of gelatin are described above.
Shunts Having a Variable Inner Diameter
In other aspects, some embodiments generally provide a shunt having a variable inner diameter. In particular embodiments, the diameter increases from inlet to outlet of the shunt. By having a variable inner diameter that increases from inlet to outlet, a pressure gradient is produced and particulate that may otherwise clog the inlet of the shunt is forced through the inlet due to the pressure gradient. Further, the particulate will flow out of the shunt because the diameter only increases after the inlet.
In exemplary embodiments, the inner diameter may range in size from about 10 μm to about 200 μm, and the inner diameter at the outlet may range in size from about 15 μm to about 300 μm. Some embodiments encompasses shunts of different shapes and different dimensions, and some embodiments of the shunt may be any shape or any dimension that may be accommodated by the eye. In certain embodiments, the intraocular shunt is of a cylindrical shape and has an outside cylindrical wall and a hollow interior. The shunt may have an inside diameter from approximately 10 μm to approximately 250 μm, an outside diameter from diameter from approximately 100 μm to approximately 450 μm, such as approximately 190 μm to approximately 300 μm, and a length from approximately 0.5 mm to approximately 20 mm, such as from approximately 2 mm to approximately 10 mm. Some embodiments of the shunt may be made from any biocompatible material. An exemplary material is gelatin. Methods of making shunts composed of gelatin are described above.
Shunts Having Pronged Ends
In other aspects, some embodiments generally provide shunts for facilitating conduction of fluid flow away from an organ, the shunt including a body, in which at least one end of the shunt is shaped to have a plurality of prongs. Such shunts reduce probability of the shunt clogging after implantation because fluid can enter or exit the shunt by any space between the prongs even if one portion of the shunt becomes clogged with particulate.
Prongs 253a-d can have any shape (i.e., width, length, height).
Some embodiments encompass shunts of different shapes and different dimensions, and some embodiments of the shunt may be any shape or any dimension that may be accommodated by the eye. In certain embodiments, the intraocular shunt is of a cylindrical shape and has an outside cylindrical wall and a hollow interior. The shunt may have an inside diameter from approximately 10 μm to approximately 250 μm, an outside diameter from approximately 100 μm to approximately 450 μm, and a length from approximately 2 mm to approximately 10 mm. Some embodiments of the shunt may be made from any biocompatible material. An exemplary material is gelatin. Methods of making shunts composed of gelatin are described above.
Shunts Having a Longitudinal Slit
In other aspects, some embodiments generally provide a shunt for draining fluid from an anterior chamber of an eye that includes a hollow body defining an inlet configured to receive fluid from an anterior chamber of the eye and an outlet configured to direct the fluid to a location of lower pressure with respect to the anterior chamber; the shunt being configured such that at least one end of the shunt includes a longitudinal slit. Such shunts reduce probability of the shunt clogging after implantation because the end(s) of the shunt can more easily pass particulate which would generally clog a shunt lacking the slits.
Longitudinal slit 255 can have any shape (i.e., width, length, height).
Some embodiments encompass shunts of different shapes and different dimensions, and some embodiments of the shunt may be any shape or any dimension that may be accommodated by the eye. In certain embodiments, the intraocular shunt is of a cylindrical shape and has an outside cylindrical wall and a hollow interior. The shunt may have an inside diameter from approximately 10 μm to approximately 250 μm, an outside diameter from approximately 100 μm to approximately 450 μm, and a length from approximately 2 mm to approximately 10 mm. Some embodiments of the shunt may be made from any biocompatible material. An exemplary material is gelatin. Methods of making shunts composed of gelatin are described above.
Pharmaceutical Agents
In certain embodiments, some embodiments of the shunt may be coated or impregnated with at least one pharmaceutical and/or biological agent or a combination thereof. The pharmaceutical and/or biological agent may coat or impregnate an entire exterior of the shunt, an entire interior of the shunt, or both. Alternatively, the pharmaceutical or biological agent may coat and/or impregnate a portion of an exterior of the shunt, a portion of an interior of the shunt, or both. Methods of coating and/or impregnating an intraocular shunt with a pharmaceutical and/or biological agent are known in the art. See for example, Darouiche (U.S. Pat. Nos. 7,790,183; 6,719,991; 6,558,686; 6,162,487; 5,902,283; 5,853,745; and 5,624,704) and Yu et al. (U.S. Pat. Pub. No. 2008/0108933). The content of each of these references is incorporated by reference herein its entirety.
In certain embodiments, the exterior portion of the shunt that resides in the anterior chamber after implantation (e.g., about 1 mm of the proximal end of the shunt) is coated and/or impregnated with the pharmaceutical or biological agent. In other embodiments, the exterior of the shunt that resides in the scleral tissue after implantation of the shunt is coated and/or impregnated with the pharmaceutical or biological agent. In other embodiments, the exterior portion of the shunt that resides in the area of lower pressure, such as the intrascleral space, the intra-Tenon's space, or the subconjunctival space, after implantation is coated and/or impregnated with the pharmaceutical or biological agent. In embodiments in which the pharmaceutical or biological agent coats and/or impregnates the interior of the shunt, the agent may be flushed through the shunt and into the area of lower pressure (e.g., the intra-Tenon's space or the subconjunctival space).
Any pharmaceutical and/or biological agent or combination thereof may be used with some embodiments of the shunt. The pharmaceutical and/or biological agent may be released over a short period of time (e.g., seconds) or may be released over longer periods of time (e.g., days, weeks, months, or even years). Exemplary agents include anti-mitotic pharmaceuticals such as Mitomycin-C or 5-Fluorouracil, anti-VEGF (such as Lucintes, Macugen, Avastin, VEGF or steroids).
Reference is now made to
Distal portion 301b includes a capsule 329 and a hollow sleeve 330. Capsule 329 and sleeve 330 may be formed integrally or may be separate components that are coupled or connected to each other. The hollow sleeve 330 is configured for insertion into an eye and to extend into an anterior chamber of an eye.
The hollow shaft 304 may include a sharpened distal end. With reference to
A distal end of sleeve 330 may optionally include a protrusion 331 (
Further, in some embodiments, the deployment device can be advanced into the anterior chamber angle on the opposite side of the eye from which the device entered the eye. With some embodiments of the device, upon advancement of the device 300 across an anterior chamber of the eye, the protrusion 331 at the distal end of the hollow sleeve 330 will contact a partially or completely closed anterior chamber angle, and continued advancement of the device 300 will result in the protrusion 331 re-opening the partially or completely closed anterior chamber angle. Once re-opened by the protrusion 131, the device 300 can be moved into proper position for exposure of the hollow shaft 304, which will advance through the sclera for deployment of an intraocular shunt. The protrusion 331, provides adequate surface area at the distal end of sleeve 330, thus preventing sleeve 330 from entering the tissue of the eye that is blocking access the trabecular meshwork (e.g., the iris).
In certain embodiments, protrusion 331 has a substantially flat bottom portion and an angled top portion (
Referring back to
Conversely, if sleeve 330 enters the anterior chamber 341 at too steep an angle, i.e., the protrusion 331 hit the iris 344 below the anterior chamber angle 343, the substantially flat bottom portion of the protrusion 331 causes the sleeve 330 to deflect off the iris 344 and proceed is a direction parallel to the iris 344 until the protrusion 331 is fit within the anterior chamber angle 343 of the eye 340 (
In certain embodiments, protrusion 331 is not required. In these embodiments, the sleeve 330 is of a sufficient outer diameter such that the sleeve itself may serve the function of the protrusion as described above. In these embodiments, a distal end of the sleeve is shaped to have a flat bottom portion and an angled top portion. In other embodiments, a goniolens can be used to visualize advancement of the device within the eye, and thus the configuration of the distal end of the sleeve 330 is not important for proper shunt deployment using some embodiments of the device.
Referring back to
Housing 301 and protrusion 331 may be made of any material that is suitable for use in medical devices. For example, housing 301 and protrusion 331 may be made of a lightweight aluminum or a biocompatible plastic material. Examples of such suitable plastic materials include polycarbonate and other polymeric resins such as DELRIN and ULTEM. In certain embodiments, housing 301 and protrusion 331 are made of a material that may be autoclaved, and thus allow for housing 301 and protrusion 331 to be re-usable. Alternatively, device 300, may be sold as a one-time-use device, and thus the material of the housing and the protrusion does not need to be a material that is autoclavable.
Deployment into the eye of an intraocular shunt, such as the shunts described herein, in accordance with some methods can be achieved using a hollow shaft configured to hold the shunt, as described herein. The hollow shaft can be coupled to a deployment device or part of the deployment device itself. Deployment devices that are suitable for use with some methods include but are not limited to the deployment devices described in U.S. Pat. Nos. 6,007,511, 6,544,249, and U.S. Pat. Pub. No. US2008/0108933, the contents of each of which are hereby incorporated by reference in their entireties. In other embodiments, the deployment devices are devices as described in co-pending and co-owned U.S. patent application Ser. No. 12/946,222 filed on Nov. 15, 2010, the entire content of which is incorporated by reference herein.
In still other embodiments, some methods are conducted using the deployment device 400 depicted in
Housing 401 is shown having a larger proximal portion that tapers to a distal portion. The distal portion includes a hollow sleeve 405. The hollow sleeve 405 is configured for insertion into an eye and to extend into an anterior chamber of an eye. The hollow sleeve is visible within an anterior chamber of an eye. The sleeve may include an edge at a distal end that provides resistance feedback to an operator upon insertion of the deployment device 400 within an eye of a person. Upon advancement of the device 400 across an anterior chamber of the eye, the hollow sleeve 405 will eventually contact the sclera, providing resistance feedback to an operator that no further advancement of the device 400 is necessary. The edge of the sleeve 405, prevents the shaft 404 from accidentally being pushed too far through the sclera. A temporary guard 408 is configured to fit around sleeve 405 and extend beyond an end of sleeve 405. The guard is used during shipping of the device and protects an operator from a distal end of a hollow shaft 404 that extends beyond the end of the sleeve 405. The guard is removed prior to use of the device.
Housing 401 is open at its proximal end, such that a portion of a deployment mechanism 403 may extend from the proximal end of the housing 401. A distal end of housing 401 is also open such that at least a portion of a hollow shaft 404 may extend through and beyond the distal end of the housing 401. Housing 401 further includes a slot 406 through which an operator, such as a surgeon, using the device 400 may view an indicator 407 on the deployment mechanism 403.
Housing 401 may be made of any material that is suitable for use in medical devices. For example, housing 401 may be made of a lightweight aluminum or a biocompatible plastic material. Examples of such suitable plastic materials include polycarbonate and other polymeric resins such as DELRIN and ULTEM. In certain embodiments, housing 401 is made of a material that may be autoclaved, and thus allow for housing 401 to be re-usable. Alternatively, device 400, may be sold as a one-time-use device, and thus the material of the housing does not need to be a material that is autoclavable.
Housing 401 may be made of multiple components that connect together to form the housing.
Deployment mechanism 403 includes a distal portion 409 and a proximal portion 410. The deployment mechanism 403 is configured such that distal portion 409 is movable within proximal portion 410. More particularly, distal portion 409 is capable of partially retracting to within proximal portion 410.
In this embodiment, the distal portion 409 is shown to taper to a connection with a hollow shaft 404. This embodiment is illustrated such that the connection between the hollow shaft 404 and the distal portion 409 of the deployment mechanism 403 occurs inside the housing 401. Hollow shaft 404 may be removable from the distal portion 409 of the deployment mechanism 403. Alternatively, the hollow shaft 404 may be permanently coupled to the distal portion 409 of the deployment mechanism 403.
Generally, hollow shaft 404 is configured to hold an intraocular shunt 415. An exemplary intraocular shunt 415 in shown in
The shaft 404 may be any length. A usable length of the shaft may be anywhere from about 5 mm to about 40 mm, and is 15 mm in certain embodiments. In certain embodiments, the shaft is straight. In other embodiments, shaft 404 is of a shape other than straight, for example a shaft having a bend along its length or a shaft having an arcuate portion. Exemplary shaped shafts are shown for example in Yu et al. (U.S. Pat. Pub. No. 2008/0108933). In particular embodiments, the shaft includes a bend at a distal portion of the shaft. In other embodiments, a distal end of the shaft is beveled or is sharpened to a point.
The shaft 404 may hold the shunt at least partially within the hollow interior of the shaft 404. In other embodiments, the shunt is held completely within the hollow interior of the shaft 404. Alternatively, the hollow shaft may hold the shunt on an outer surface of the shaft 404. In particular embodiments, the shunt is held within the hollow interior of the shaft 404. In certain embodiments, the hollow shaft is a needle having a hollow interior. Needles that are configured to hold an intraocular shunt are commercially available from Terumo Medical Corp. (Elkington, Md.).
A proximal portion of the deployment mechanism 403 includes optional grooves 416 to allow for easier gripping by an operator for easier rotation of the deployment mechanism, which will be discussed in more detail below. The proximal portion 410 of the deployment mechanism also includes at least one indicator that provides feedback to an operator as to the state of the deployment mechanism. The indicator may be any type of indicator known in the art, for example a visual indicator, an audio indicator, or a tactile indicator.
The proximal portion 410 includes a stationary portion 410b and a rotating portion 410a. The proximal portion 410 includes a channel 412 that runs part of the length of stationary portion 410b and the entire length of rotating portion 410a. The channel 412 is configured to interact with a protrusion 417 on an interior portion of housing component 401a (
Referring back to
Reference is now made to
In the pre-deployment or insertion configuration, the distal portion 401b of the housing 401 is in an extended position, with spring 421 in a relaxed state (
The deployment mechanism 403 is configured such that member 414a abuts a distal end of the first portion 413a1 of channel 413a, and member 414b abut a proximal end of the first portion 413b1 of channel 413b (
Insertion without the use of an optical apparatus that contacts the eye, or any optical apparatus, is possible because of various features of the device described above and reviewed here briefly. The shape of the protrusion 431 is such that it corrects for an insertion angle that is too steep or too shallow, ensuring that the sleeve 430 is fitted into the anterior chamber angle of the eye, the place for proper deployment of an intraocular shunt. Further, the shape of the protrusion provides adequate surface area at the distal end of sleeve 430 to prevent enough force from being generated at the distal end of sleeve 430 that would result in sleeve 430 entering an improper portion of the sclera 442 (if the insertion angle is too shallow) or entering an improper portion of the iris 444 (if the insertion angle is too steep). Additionally, since the hollow shaft 404 is fully disposed within the sleeve 430, it cannot pierce tissue of the eye until it is extended from the sleeve 430. Thus, if the insertion angle is too shallow or too steep, the protrusion 431 can cause movement and repositioning of the sleeve 430 so that the sleeve 430 is properly positioned to fit in the anterior chamber angle of the eye for proper deployment of the shunt. Due to these features of device 400, some embodiments of the device provide for deploying intraocular shunts without use of an optical apparatus that contacts the eye, preferably without use of any optical apparatus.
Once the device has been inserted into the eye and the protrusion 431 and the sleeve 430 are fitted within the anterior chamber angle of the eye, the hollow shaft 404 may be extended from within the sleeve 430. Referring now to
Retraction of the distal portion 401b of housing 401 to within proximal portion 401a of housing 401 is accomplished by an operator continuing to apply force to advance device 400 after the protrusion 431 and the sleeve 430 are fitted within the anterior chamber angle of the eye. The surface area of protrusion 431 prevents the application of the additional force by the operator from advancing sleeve 430 into the sclera 434. Rather, the additional force applied by the operator results in engagement of spring mechanism 420 and compression of spring 421 within spring mechanism 420. Compression of spring 420 results in retraction of distal portion 401b of housing 401 to within proximal portion 401a of housing 401. The amount of retraction of distal portion 401b of housing 401 to within proximal portion 401a of housing 401 is limited by member 422 that acts as a stopper and limits axial retraction of distal portion 401b within proximal portion 401a.
Retraction of distal portion 401b of housing 401 to within proximal portion 401a of housing 401 results in extension of hollow shaft 404, which now extends beyond the distal end of sleeve 430 and advances through the sclera 442 to an area of lower pressure than the anterior chamber (see e.g.,
In
The distal end of shaft 404 may be beveled to assist in piercing the sclera and advancing the distal end of the shaft 404 through the sclera. In this figure, the distal end of the shaft 404 is shown to have a double bevel (See also
Referring to
Additionally, the flexibility of the hollow shaft 404 allows it to continually bend and flex in response to the anatomy as the hollow shaft 404 advances from the sleeve 430. The hollow shaft 404 is advanced until a distal portion of the hollow shaft 404 is within the suprachoroidal space. In this configuration, the shunt 415 is still completely disposed within the shaft 404. The distal end of hollow shaft 404 may be beveled to assist in piercing the sclera and advancing the distal end of the hollow shaft 404 through the sclera.
At this point, an amount of BSS/steroid or other drug can be optionally injected through the hollow shaft and implant into a lower end of the target space to create a primed space for outflow and to deliver antifibrotic or other drugs to that new drainage space.
Reference is now made to
In the first stage of shunt deployment, the pusher component is engaged and the pusher partially deploys the shunt from the deployment device. During the first stage, rotating portion 410a of the proximal portion 410 of the deployment mechanism 403 is rotated, resulting in movement of members 414a and 414b along first portions 413a1 and 413b1 in channels 413a and 413b. Since the first portion 413a1 of channel 413a is straight and runs perpendicular to the length of the rotating portion 410a, rotation of rotating portion 410a does not cause axial movement of member 414a. Without axial movement of member 414a, there is no retraction of the distal portion 409 to within the proximal portion 410 of the deployment mechanism 403. Since the first portion 413b1 of channel 413b runs diagonally along the length of the rotating portion 410a, upwardly toward a distal end of the deployment mechanism 403, rotation of rotating portion 410a causes axial movement of member 414b toward a distal end of the device. Axial movement of member 414b toward a distal end of the device results in forward advancement of the pusher component 418 within the hollow shaft 404. Such movement of pusher component 418 results in partially deployment of the shunt 415 from the shaft 404.
Reference is now made to
Referring to
Referring to
Referring to
Three Stage Deployment Mechanism
Another embodiment by which the hollow shaft 404 may be extended from the sleeve 430 involves a deployment mechanism that is a three-stage mechanism. The three-stage mechanism operates similarly to the above described device that uses a spring loaded distal portion and a two-stage deployment mechanism. In the three-stage system, the channels of the deployment mechanism are extended to accommodate the new first stage. The newly added portion of the channels run diagonally upward along the length of the rotating portion toward the proximal end of the deployment mechanism. Axial movement by the members within the channels results in the extension of the hollow shaft 404 from the sleeve 430. The new first stage replaces the spring loaded distal portion and results in extension of the hollow shaft 404 from the sleeve 430. The engagement of the pusher component 418 becomes the second stage and retraction of the distal portion 409 of deployment mechanism 403 to within the proximal portion 410 of the deployment mechanism 403 becomes the third stage. The second and third stages of the three-stage system are the same as the first and second stages of the two-stage system and operate as described above. Rotation of the rotating portion of the distal portion of the deployment mechanism sequentially extends the hollow shaft from the sleeve, engages the pusher component and then engages the retraction component.
Referring now to
As will be appreciated by one skilled in the art, individual features of some embodiments may be used separately or in any combination. Particularly, it is contemplated that one or more features of the individually described above embodiments may be combined into a single shunt.
References and citations to other documents, such as patents, patent applications, patent publications, journals, books, papers, web contents, have been made throughout this disclosure. All such documents are hereby incorporated herein by reference in their entirety for all purposes.
The inventions may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The foregoing embodiments are therefore to be considered in all respects illustrative rather than limiting on the inventions described herein.
This application is a continuation of U.S. patent application Ser. No. 14/313,970, filed Jun. 24, 2014; U.S. patent application Ser. No. 14/313,970 is a continuation-in-part of U.S. patent application Ser. No. 12/946,572, filed on Nov. 15, 2010, now U.S. Pat. No. 8,852,256; U.S. patent application Ser. No. 14/313,970 is also a continuation-in-part of U.S. patent application Ser. No. 12/946,222, filed on Nov. 15, 2010, now abandoned; U.S. patent application Ser. No. 14/313,970 is also a continuation-in-part of U.S. patent application Ser. No. 12/946,240, filed on Nov. 15, 2010, now U.S. Pat. No. 8,828,070; U.S. patent application Ser. No. 14/313,970 is also a continuation-in-part of U.S. patent application Ser. No. 12/946,251, filed on Nov. 15, 2010, now U.S. Pat. No. 9,095,411; U.S. patent application Ser. No. 14/313,970 is also a continuation-in-part of U.S. patent application Ser. No. 12/946,263, filed on Nov. 15, 2010, now U.S. Pat. No. 8,801,766; U.S. patent application Ser. No. 14/313,970 is also a continuation-in-part of U.S. patent application Ser. No. 13/314,927, filed Dec. 8, 2011, now abandoned, which is a continuation-in-part of U.S. patent application Ser. No. 12/946,351, filed on Nov. 15, 2010, now abandoned; U.S. patent application Ser. No. 14/313,970 is also a continuation-in-part of U.S. patent application Ser. No. 12/946,556, filed on Nov. 15, 2010, now abandoned; U.S. patent application Ser. No. 14/313,970 is also a continuation-in-part of U.S. patent application Ser. No. 14/263,957, filed on Apr. 28, 2014, now U.S. Pat. No. 9,283,116, which is a continuation of U.S. patent application Ser. No. 12/946,645, filed on Nov. 15, 2010, now U.S. Pat. No. 8,721,702; U.S. patent application Ser. No. 14/313,970 is also a continuation-in-part of U.S. patent application Ser. No. 14/191,340, filed on Feb. 26, 2014, now U.S. Pat. No. 9,192,516, which is a continuation of U.S. patent application Ser. No. 12/946,653, filed on Nov. 15, 2010, now U.S. Pat. No. 8,663,303; U.S. patent application Ser. No. 14/313,970 is also a continuation-in-part of U.S. patent application Ser. No. 12/946,565, filed on Nov. 15, 2010, now U.S. Pat. No. 8,974,511; U.S. patent application Ser. No. 14/313,970 is also a continuation-in-part of U.S. patent application Ser. No. 13/336,758, filed on Dec. 23, 2011, now U.S. Pat. No. 8,852,137, which is a continuation-in-part of U.S. patent application Ser. No. 12/946,351, filed on Nov. 15, 2010, now abandoned, and which is a continuation-in-part of U.S. patent application Ser. No. 12/946,222, filed on Nov. 15, 2010, now abandoned; U.S. patent application Ser. No. 14/313,970 is also a continuation-in-part of U.S. patent application Ser. No. 13/336,803, filed on Dec. 23, 2011, now U.S. Pat. No. 8,758,290, which is a continuation-in-part of U.S. patent application Ser. No. 12/946,351, filed on Nov. 15, 2010, now abandoned, and which is a continuation-in-part of U.S. patent application Ser. No. 12/946,222, filed on Nov. 15, 2010, now abandoned; U.S. patent application Ser. No. 14/313,970 is also a continuation-in-part of U.S. patent application Ser. No. 13/895,170, filed on May 15, 2013, which is a continuation of International Pat. App. No. PCT/US2011/060820, filed on Nov. 15, 2011, which claims the benefit of and priority to U.S. patent application Ser. No. 12/946,210, filed on Nov. 15, 2010, now U.S. Pat. No. 8,308,701; and U.S. patent application Ser. No. 14/313,970 is also a continuation-in-part of U.S. patent application Ser. No. 13/952,543, filed on Jul. 26, 2013, now U.S. Pat. No. 9,017,276, which is a continuation of U.S. patent application Ser. No. 12/946,542, filed on Nov. 15, 2010, now abandoned; the entireties of each of these applications and patents are incorporated herein by reference.
| Number | Name | Date | Kind |
|---|---|---|---|
| 3788327 | Donowitz et al. | Jan 1974 | A |
| 3960150 | Hussain et al. | Jun 1976 | A |
| 4090530 | Lange | May 1978 | A |
| 4402308 | Scott | Sep 1983 | A |
| 4562463 | Lipton | Dec 1985 | A |
| 4583117 | Lipton et al. | Apr 1986 | A |
| 4700692 | Baumgartner | Oct 1987 | A |
| 4722724 | Schocket | Feb 1988 | A |
| 4744362 | Grundler | May 1988 | A |
| 4750901 | Molteno | Jun 1988 | A |
| 4787885 | Binder | Nov 1988 | A |
| 4804382 | Turina et al. | Feb 1989 | A |
| 4820626 | Williams et al. | Apr 1989 | A |
| 4826478 | Schocket | May 1989 | A |
| 4836201 | Patton et al. | Jun 1989 | A |
| 4848340 | Bille et al. | Jul 1989 | A |
| 4863457 | Lee | Sep 1989 | A |
| 4902292 | Joseph | Feb 1990 | A |
| 4911161 | Schechter | Mar 1990 | A |
| 4915684 | MacKeen et al. | Apr 1990 | A |
| 4934363 | Smith et al. | Jun 1990 | A |
| 4936825 | Ungerleider | Jun 1990 | A |
| 4946436 | Smith | Aug 1990 | A |
| 4968296 | Ritch et al. | Nov 1990 | A |
| 4978352 | Fedorov et al. | Dec 1990 | A |
| 5041081 | Odrich | Aug 1991 | A |
| 5057098 | Zelman | Oct 1991 | A |
| 5071408 | Ahmed | Dec 1991 | A |
| 5092837 | Ritch et al. | Mar 1992 | A |
| 5098426 | Sklar et al. | Mar 1992 | A |
| 5098443 | Parel et al. | Mar 1992 | A |
| 5162641 | Fountain | Nov 1992 | A |
| 5178604 | Baerveldt et al. | Jan 1993 | A |
| 5180362 | Worst | Jan 1993 | A |
| 5201750 | Hocherl et al. | Apr 1993 | A |
| 5207660 | Lincoff | May 1993 | A |
| 5273530 | Del Cerro | Dec 1993 | A |
| 5275622 | Lazarus | Jan 1994 | A |
| 5290295 | Querals et al. | Mar 1994 | A |
| 5300020 | L'Esperance, Jr. | Apr 1994 | A |
| 5333619 | Burgio | Aug 1994 | A |
| 5338291 | Speckman et al. | Aug 1994 | A |
| 5342370 | Simon et al. | Aug 1994 | A |
| 5360339 | Rosenberg | Nov 1994 | A |
| 5368015 | Wilk | Nov 1994 | A |
| 5370607 | Memmen | Dec 1994 | A |
| 5399951 | Lavallee et al. | Mar 1995 | A |
| 5410638 | Colgate et al. | Apr 1995 | A |
| 5443505 | Wong et al. | Aug 1995 | A |
| 5472439 | Hurd | Dec 1995 | A |
| 5476445 | Baerveldt et al. | Dec 1995 | A |
| 5516522 | Peyman et al. | May 1996 | A |
| 5520631 | Nordquist et al. | May 1996 | A |
| 5558629 | Baerveldt et al. | Sep 1996 | A |
| 5558630 | Fisher | Sep 1996 | A |
| 5573544 | Simon et al. | Nov 1996 | A |
| 5601094 | Reiss | Feb 1997 | A |
| 5651782 | Simon et al. | Jul 1997 | A |
| 5656026 | Joseph | Aug 1997 | A |
| 5665093 | Atkins et al. | Sep 1997 | A |
| 5665114 | Weadock et al. | Sep 1997 | A |
| 5670161 | Healy et al. | Sep 1997 | A |
| 5676679 | Simon et al. | Oct 1997 | A |
| 5688562 | Hsiung | Nov 1997 | A |
| 5695474 | Daugherty | Dec 1997 | A |
| 5702414 | Richter et al. | Dec 1997 | A |
| 5704907 | Nordquist et al. | Jan 1998 | A |
| 5707376 | Kavteladze et al. | Jan 1998 | A |
| 5722948 | Gross | Mar 1998 | A |
| 5763491 | Brandt et al. | Jun 1998 | A |
| 5824072 | Wong | Oct 1998 | A |
| 5868697 | Richter et al. | Feb 1999 | A |
| 5908449 | Bruchman et al. | Jun 1999 | A |
| 5932299 | Katoot | Aug 1999 | A |
| 5938583 | Grimm | Aug 1999 | A |
| 5964747 | Eaton et al. | Oct 1999 | A |
| 5968058 | Richter et al. | Oct 1999 | A |
| 6007511 | Prywes | Dec 1999 | A |
| 6007578 | Schachar | Dec 1999 | A |
| 6050970 | Baerveldt | Apr 2000 | A |
| 6086543 | Anderson et al. | Jul 2000 | A |
| 6102045 | Nordquist et al. | Aug 2000 | A |
| 6146366 | Schachar | Nov 2000 | A |
| 6159218 | Aramant et al. | Dec 2000 | A |
| 6165210 | Lau et al. | Dec 2000 | A |
| 6203513 | Yaron et al. | Mar 2001 | B1 |
| 6228023 | Zaslavsky et al. | May 2001 | B1 |
| 6228873 | Brandt et al. | May 2001 | B1 |
| 6261256 | Ahmed | Jul 2001 | B1 |
| 6264665 | Yu et al. | Jul 2001 | B1 |
| 6280468 | Schachar | Aug 2001 | B1 |
| 6413540 | Yaacobi | Jul 2002 | B1 |
| 6450937 | Mercereau et al. | Sep 2002 | B1 |
| 6468283 | Richter et al. | Oct 2002 | B1 |
| 6471666 | Odrich | Oct 2002 | B1 |
| 6483930 | Musgrave et al. | Nov 2002 | B1 |
| 6510600 | Yaron et al. | Jan 2003 | B2 |
| 6514238 | Hughes | Feb 2003 | B1 |
| 6524275 | Lynch et al. | Feb 2003 | B1 |
| 6533768 | Hill | Mar 2003 | B1 |
| 6544249 | Yu et al. | Apr 2003 | B1 |
| 6558342 | Yaron et al. | May 2003 | B1 |
| 6595945 | Brown | Jul 2003 | B2 |
| 6638239 | Bergheim et al. | Oct 2003 | B1 |
| 6699210 | Williams et al. | Mar 2004 | B2 |
| 6726664 | Yaron et al. | Apr 2004 | B2 |
| D490152 | Myall et al. | May 2004 | S |
| 6736791 | Tu et al. | May 2004 | B1 |
| 6752753 | Hoskins et al. | Jun 2004 | B1 |
| 6780164 | Bergheim et al. | Aug 2004 | B2 |
| 6881198 | Brown | Apr 2005 | B2 |
| 6936053 | Weiss | Aug 2005 | B1 |
| 6939298 | Brown et al. | Sep 2005 | B2 |
| 6955656 | Bergheim et al. | Oct 2005 | B2 |
| 7008396 | Straub | Mar 2006 | B1 |
| 7037335 | Freeman et al. | May 2006 | B2 |
| 7041077 | Shields | May 2006 | B2 |
| 7094225 | Tu et al. | Aug 2006 | B2 |
| 7118547 | Dahan | Oct 2006 | B2 |
| 7135009 | Tu et al. | Nov 2006 | B2 |
| 7163543 | Smedley et al. | Jan 2007 | B2 |
| 7186232 | Smedley et al. | Mar 2007 | B1 |
| 7207980 | Christian et al. | Apr 2007 | B2 |
| 7273475 | Tu et al. | Sep 2007 | B2 |
| 7291125 | Coroneo | Nov 2007 | B2 |
| 7297130 | Bergheim et al. | Nov 2007 | B2 |
| 7331984 | Tu et al. | Feb 2008 | B2 |
| 7431709 | Pinchuk et al. | Oct 2008 | B2 |
| 7431710 | Tu et al. | Oct 2008 | B2 |
| 7458953 | Peyman | Dec 2008 | B2 |
| 7481816 | Richter et al. | Jan 2009 | B2 |
| 7488303 | Haffner et al. | Feb 2009 | B1 |
| 7563241 | Tu et al. | Jul 2009 | B2 |
| 7594899 | Pinchuk et al. | Sep 2009 | B2 |
| 7625384 | Eriksson et al. | Dec 2009 | B2 |
| 7658729 | Hull | Feb 2010 | B2 |
| 7670310 | Yaron et al. | Mar 2010 | B2 |
| 7708711 | Tu et al. | May 2010 | B2 |
| 7722549 | Nakao | May 2010 | B2 |
| 7815592 | Coroneo | Oct 2010 | B2 |
| 7837644 | Pinchuk et al. | Nov 2010 | B2 |
| 7850638 | Theodore Coroneo | Dec 2010 | B2 |
| 7857782 | Tu et al. | Dec 2010 | B2 |
| 7867186 | Haffner et al. | Jan 2011 | B2 |
| 7867205 | Bergheim et al. | Jan 2011 | B2 |
| 7879001 | Haffner et al. | Feb 2011 | B2 |
| 7879079 | Tu et al. | Feb 2011 | B2 |
| 7892282 | Shepherd | Feb 2011 | B2 |
| 7951155 | Smedley et al. | May 2011 | B2 |
| 8007459 | Haffner et al. | Aug 2011 | B2 |
| 8062244 | Tu et al. | Nov 2011 | B2 |
| 8075511 | Tu et al. | Dec 2011 | B2 |
| 8109896 | Nissan et al. | Feb 2012 | B2 |
| 8118768 | Tu et al. | Feb 2012 | B2 |
| 8128588 | Coroneo | Mar 2012 | B2 |
| 8167939 | Silvestrini et al. | May 2012 | B2 |
| 8172899 | Silvestrini et al. | May 2012 | B2 |
| 8262726 | Silvestrini et al. | Sep 2012 | B2 |
| 8267882 | Euteneuer et al. | Sep 2012 | B2 |
| 8273050 | Bergheim et al. | Sep 2012 | B2 |
| 8277437 | Seal et al. | Oct 2012 | B2 |
| 8308701 | Horvath et al. | Nov 2012 | B2 |
| 8313454 | Yaron et al. | Nov 2012 | B2 |
| 8333742 | Bergheim et al. | Dec 2012 | B2 |
| 8337393 | Silverstrini et al. | Dec 2012 | B2 |
| 8337445 | Tu et al. | Dec 2012 | B2 |
| 8337509 | Schieber et al. | Dec 2012 | B2 |
| 8348877 | Tu et al. | Jan 2013 | B2 |
| 8377122 | Silvestrini et al. | Feb 2013 | B2 |
| 8425449 | Wardle et al. | Apr 2013 | B2 |
| 8444589 | Silvestrini | May 2013 | B2 |
| 8486000 | Coroneo | Jul 2013 | B2 |
| 8486086 | Yaron et al. | Jul 2013 | B2 |
| 8506515 | Burns et al. | Aug 2013 | B2 |
| 8512404 | Frion et al. | Aug 2013 | B2 |
| 8529492 | Clauson et al. | Sep 2013 | B2 |
| 8529494 | Euteneuer et al. | Sep 2013 | B2 |
| 8535333 | de Juan, Jr. et al. | Sep 2013 | B2 |
| 8545430 | Silvestrini | Oct 2013 | B2 |
| 8551166 | Schieber et al. | Oct 2013 | B2 |
| 8574294 | Silvestrini et al. | Nov 2013 | B2 |
| 8579846 | Tu et al. | Nov 2013 | B2 |
| 8585629 | Grabner et al. | Nov 2013 | B2 |
| 8663303 | Horvath et al. | Mar 2014 | B2 |
| 8721702 | Romoda et al. | May 2014 | B2 |
| 8758290 | Horvath et al. | Jun 2014 | B2 |
| 8765210 | Romoda et al. | Jul 2014 | B2 |
| 8801766 | Reitsamer et al. | Aug 2014 | B2 |
| 8828070 | Romoda et al. | Sep 2014 | B2 |
| 8852136 | Horvath et al. | Oct 2014 | B2 |
| 8852137 | Horvath et al. | Oct 2014 | B2 |
| 8852256 | Horvath et al. | Oct 2014 | B2 |
| 8974511 | Horvath et al. | Mar 2015 | B2 |
| 9017276 | Horvath et al. | Apr 2015 | B2 |
| 9044301 | Pinchuk et al. | Jun 2015 | B1 |
| 9095411 | Horvath et al. | Aug 2015 | B2 |
| 9095413 | Romoda et al. | Aug 2015 | B2 |
| 9192516 | Horvath et al. | Nov 2015 | B2 |
| 9271869 | Horvath et al. | Mar 2016 | B2 |
| 9283116 | Romoda et al. | Mar 2016 | B2 |
| 9326891 | Horvath et al. | May 2016 | B2 |
| 9393153 | Horvath | Jul 2016 | B2 |
| 20010025150 | de Juan et al. | Sep 2001 | A1 |
| 20010056254 | Cragg et al. | Dec 2001 | A1 |
| 20020087149 | McCary | Jul 2002 | A1 |
| 20020099434 | Buscemi et al. | Jul 2002 | A1 |
| 20020133168 | Smedley et al. | Sep 2002 | A1 |
| 20020177856 | Richter et al. | Nov 2002 | A1 |
| 20020193725 | Odrich | Dec 2002 | A1 |
| 20030015203 | Makower et al. | Jan 2003 | A1 |
| 20030050574 | Krueger | Mar 2003 | A1 |
| 20030060752 | Bergheim et al. | Mar 2003 | A1 |
| 20030079329 | Yaron et al. | May 2003 | A1 |
| 20030093084 | Nissan et al. | May 2003 | A1 |
| 20030097053 | Itoh | May 2003 | A1 |
| 20030181848 | Bergheim et al. | Sep 2003 | A1 |
| 20030187383 | Weber et al. | Oct 2003 | A1 |
| 20030187384 | Bergheim et al. | Oct 2003 | A1 |
| 20030236483 | Ren | Dec 2003 | A1 |
| 20030236484 | Lynch et al. | Dec 2003 | A1 |
| 20040077987 | Rapacki et al. | Apr 2004 | A1 |
| 20040147870 | Burns et al. | Jul 2004 | A1 |
| 20040199130 | Chornenky et al. | Oct 2004 | A1 |
| 20040210185 | Tu et al. | Oct 2004 | A1 |
| 20040210209 | Yeung et al. | Oct 2004 | A1 |
| 20040215133 | Weber et al. | Oct 2004 | A1 |
| 20040216749 | Tu | Nov 2004 | A1 |
| 20040236343 | Taylor et al. | Nov 2004 | A1 |
| 20040254519 | Tu et al. | Dec 2004 | A1 |
| 20040254520 | Porteous et al. | Dec 2004 | A1 |
| 20040254521 | Simon | Dec 2004 | A1 |
| 20040260227 | Lisk et al. | Dec 2004 | A1 |
| 20050049578 | Tu et al. | Mar 2005 | A1 |
| 20050101967 | Weber et al. | May 2005 | A1 |
| 20050143363 | De Juan et al. | Jun 2005 | A1 |
| 20050209549 | Bergheim et al. | Sep 2005 | A1 |
| 20050246023 | Yeung | Nov 2005 | A1 |
| 20050267398 | Protopsaltis et al. | Dec 2005 | A1 |
| 20050271704 | Tu et al. | Dec 2005 | A1 |
| 20050277864 | Haffner et al. | Dec 2005 | A1 |
| 20060052721 | Dunker et al. | Mar 2006 | A1 |
| 20060064112 | Perez | Mar 2006 | A1 |
| 20060074375 | Bergheim et al. | Apr 2006 | A1 |
| 20060084907 | Bergheim et al. | Apr 2006 | A1 |
| 20060106370 | Baerveldt et al. | May 2006 | A1 |
| 20060116625 | Renati et al. | Jun 2006 | A1 |
| 20060149194 | Conston et al. | Jul 2006 | A1 |
| 20060155238 | Shields | Jul 2006 | A1 |
| 20060155300 | Stamper et al. | Jul 2006 | A1 |
| 20060173397 | Tu et al. | Aug 2006 | A1 |
| 20060173446 | Dacquay et al. | Aug 2006 | A1 |
| 20060195055 | Bergheim et al. | Aug 2006 | A1 |
| 20060195056 | Bergheim et al. | Aug 2006 | A1 |
| 20060200113 | Haffner et al. | Sep 2006 | A1 |
| 20060241411 | Field et al. | Oct 2006 | A1 |
| 20060241749 | Tu et al. | Oct 2006 | A1 |
| 20070027537 | Castillejos | Feb 2007 | A1 |
| 20070093783 | Kugler et al. | Apr 2007 | A1 |
| 20070118065 | Pinchuk et al. | May 2007 | A1 |
| 20070141116 | Pinchuk et al. | Jun 2007 | A1 |
| 20070172903 | Toner et al. | Jul 2007 | A1 |
| 20070191863 | De Juan, Jr. | Aug 2007 | A1 |
| 20070202186 | Yamamoto et al. | Aug 2007 | A1 |
| 20070263172 | Mura | Nov 2007 | A1 |
| 20070276316 | Haffner et al. | Nov 2007 | A1 |
| 20070282244 | Tu et al. | Dec 2007 | A1 |
| 20070282245 | Tu et al. | Dec 2007 | A1 |
| 20070293872 | Peyman | Dec 2007 | A1 |
| 20080015633 | Abbott et al. | Jan 2008 | A1 |
| 20080027304 | Pardo et al. | Jan 2008 | A1 |
| 20080045878 | Bergheim et al. | Feb 2008 | A1 |
| 20080057106 | Erickson et al. | Mar 2008 | A1 |
| 20080108933 | Yu et al. | May 2008 | A1 |
| 20080147001 | Al-Marashi et al. | Jun 2008 | A1 |
| 20080181929 | Robinson et al. | Jul 2008 | A1 |
| 20080183121 | Smedley et al. | Jul 2008 | A2 |
| 20080249467 | Burnett et al. | Oct 2008 | A1 |
| 20080281277 | Thyzel | Nov 2008 | A1 |
| 20080312661 | Downer et al. | Dec 2008 | A1 |
| 20090036818 | Grahn et al. | Feb 2009 | A1 |
| 20090043321 | Conston et al. | Feb 2009 | A1 |
| 20090124973 | D'Agostino et al. | May 2009 | A1 |
| 20090137983 | Bergheim et al. | May 2009 | A1 |
| 20090138081 | Bergheim et al. | May 2009 | A1 |
| 20090182421 | Silvestrini et al. | Jul 2009 | A1 |
| 20090209910 | Kugler et al. | Aug 2009 | A1 |
| 20090216106 | Takii | Aug 2009 | A1 |
| 20090264813 | Chang | Oct 2009 | A1 |
| 20090270890 | Robinson et al. | Oct 2009 | A1 |
| 20090281520 | Highley et al. | Nov 2009 | A1 |
| 20090287136 | Castillejos | Nov 2009 | A1 |
| 20100004581 | Brigatti et al. | Jan 2010 | A1 |
| 20100010416 | Juan, Jr. et al. | Jan 2010 | A1 |
| 20100063478 | Selkee | Mar 2010 | A1 |
| 20100098772 | Robinson et al. | Apr 2010 | A1 |
| 20100100104 | Yu et al. | Apr 2010 | A1 |
| 20100119696 | Yu et al. | May 2010 | A1 |
| 20100121248 | Yu et al. | May 2010 | A1 |
| 20100121249 | Yu et al. | May 2010 | A1 |
| 20100134759 | Silvestrini et al. | Jun 2010 | A1 |
| 20100137981 | Silvestrini et al. | Jun 2010 | A1 |
| 20100173866 | Hee et al. | Jul 2010 | A1 |
| 20100185138 | Yaron et al. | Jul 2010 | A1 |
| 20100191103 | Stamper et al. | Jul 2010 | A1 |
| 20100191224 | Butcher | Jul 2010 | A1 |
| 20100249691 | Van Der Mooren et al. | Sep 2010 | A1 |
| 20100274259 | Yaron et al. | Oct 2010 | A1 |
| 20100328606 | Peyman | Dec 2010 | A1 |
| 20110009874 | Wardle et al. | Jan 2011 | A1 |
| 20110028883 | Juan, Jr. et al. | Feb 2011 | A1 |
| 20110028884 | Theodore Coroneo | Feb 2011 | A1 |
| 20110046536 | Stegmann et al. | Feb 2011 | A1 |
| 20110087149 | Theodore Coroneo | Apr 2011 | A1 |
| 20110087150 | Theodore Coroneo | Apr 2011 | A1 |
| 20110087151 | Theodore Coroneo | Apr 2011 | A1 |
| 20110092878 | Tu et al. | Apr 2011 | A1 |
| 20110098627 | Wilcox | Apr 2011 | A1 |
| 20110098629 | Juan, Jr. et al. | Apr 2011 | A1 |
| 20110105987 | Bergheim et al. | May 2011 | A1 |
| 20110105990 | Silvestrini | May 2011 | A1 |
| 20110118745 | Yu et al. | May 2011 | A1 |
| 20110118835 | Silvestrini et al. | May 2011 | A1 |
| 20110230890 | Thyzel | Sep 2011 | A1 |
| 20110234976 | Kocaoglu et al. | Sep 2011 | A1 |
| 20110306915 | de Juan, Jr. et al. | Dec 2011 | A1 |
| 20120078158 | Haffner et al. | Mar 2012 | A1 |
| 20120109040 | Smedley et al. | May 2012 | A1 |
| 20120123315 | Horvath et al. | May 2012 | A1 |
| 20120123316 | Horvath et al. | May 2012 | A1 |
| 20120123317 | Horvath et al. | May 2012 | A1 |
| 20120123430 | Horvath et al. | May 2012 | A1 |
| 20120123433 | Horvath et al. | May 2012 | A1 |
| 20120123434 | Grabner et al. | May 2012 | A1 |
| 20120123435 | Romoda et al. | May 2012 | A1 |
| 20120123436 | Reitsamer et al. | May 2012 | A1 |
| 20120123437 | Horvath et al. | May 2012 | A1 |
| 20120123438 | Horvath et al. | May 2012 | A1 |
| 20120123439 | Romoda et al. | May 2012 | A1 |
| 20120123440 | Horvath et al. | May 2012 | A1 |
| 20120165720 | Horvath et al. | Jun 2012 | A1 |
| 20120165721 | Grabner et al. | Jun 2012 | A1 |
| 20120165722 | Horvath et al. | Jun 2012 | A1 |
| 20120165723 | Horvath et al. | Jun 2012 | A1 |
| 20120165933 | Haffner et al. | Jun 2012 | A1 |
| 20120197175 | Horvath et al. | Aug 2012 | A1 |
| 20120220917 | Silvestrini et al. | Aug 2012 | A1 |
| 20120226150 | Balicki et al. | Sep 2012 | A1 |
| 20120253258 | Tu et al. | Oct 2012 | A1 |
| 20120310137 | Silvestrini | Dec 2012 | A1 |
| 20130006164 | Yaron et al. | Jan 2013 | A1 |
| 20130018295 | Haffner et al. | Jan 2013 | A1 |
| 20130018296 | Bergheim et al. | Jan 2013 | A1 |
| 20130110125 | Silvestrini et al. | May 2013 | A1 |
| 20130149429 | Romoda et al. | Jun 2013 | A1 |
| 20130150770 | Horvath et al. | Jun 2013 | A1 |
| 20130158462 | Wardle et al. | Jun 2013 | A1 |
| 20130184631 | Pinchuk | Jul 2013 | A1 |
| 20130231603 | Wardle et al. | Sep 2013 | A1 |
| 20130245532 | Tu | Sep 2013 | A1 |
| 20130245573 | de Juan, Jr. et al. | Sep 2013 | A1 |
| 20130253404 | Tu | Sep 2013 | A1 |
| 20130253405 | Tu | Sep 2013 | A1 |
| 20130253406 | Horvath et al. | Sep 2013 | A1 |
| 20130253528 | Haffner et al. | Sep 2013 | A1 |
| 20130281817 | Schaller et al. | Oct 2013 | A1 |
| 20130281908 | Schaller et al. | Oct 2013 | A1 |
| 20130281910 | Tu | Oct 2013 | A1 |
| 20130310930 | Tu et al. | Nov 2013 | A1 |
| 20140018720 | Horvath et al. | Jan 2014 | A1 |
| 20140066833 | Yaron et al. | Mar 2014 | A1 |
| 20140081195 | Clauson et al. | Mar 2014 | A1 |
| 20140135916 | Clauson et al. | May 2014 | A1 |
| 20140180189 | Horvath et al. | Jun 2014 | A1 |
| 20140213958 | Clauson et al. | Jul 2014 | A1 |
| 20140236065 | Romoda et al. | Aug 2014 | A1 |
| 20140236066 | Horvath et al. | Aug 2014 | A1 |
| 20140236067 | Horvath et al. | Aug 2014 | A1 |
| 20140243730 | Horvath | Aug 2014 | A1 |
| 20140272102 | Romoda et al. | Sep 2014 | A1 |
| 20140275923 | Haffner et al. | Sep 2014 | A1 |
| 20140276332 | Crimaldi et al. | Sep 2014 | A1 |
| 20140277349 | Vad | Sep 2014 | A1 |
| 20140287077 | Romoda et al. | Sep 2014 | A1 |
| 20140303544 | Haffner et al. | Oct 2014 | A1 |
| 20140323995 | Clauson et al. | Oct 2014 | A1 |
| 20140343476 | Penhasi | Nov 2014 | A1 |
| 20140371651 | Pinchuk | Dec 2014 | A1 |
| 20150005689 | Horvath et al. | Jan 2015 | A1 |
| 20150011926 | Reitsamer et al. | Jan 2015 | A1 |
| 20150038893 | Haffner et al. | Feb 2015 | A1 |
| 20150045714 | Horvath et al. | Feb 2015 | A1 |
| 20150057591 | Horvath et al. | Feb 2015 | A1 |
| 20150133946 | Horvath et al. | May 2015 | A1 |
| 20150290035 | Horvath et al. | Oct 2015 | A1 |
| 20150374545 | Horvath et al. | Dec 2015 | A1 |
| 20160135993 | Horvath et al. | May 2016 | A1 |
| 20160135994 | Romoda et al. | May 2016 | A1 |
| 20160158063 | Romoda et al. | Jun 2016 | A1 |
| 20160250071 | Horvath et al. | Sep 2016 | A1 |
| 20160256317 | Horvath et al. | Sep 2016 | A1 |
| 20160256318 | Horvath et al. | Sep 2016 | A1 |
| 20160256319 | Horvath et al. | Sep 2016 | A1 |
| 20160256320 | Horvath et al. | Sep 2016 | A1 |
| 20160256323 | Horvath et al. | Sep 2016 | A1 |
| 20160278982 | Horvath et al. | Sep 2016 | A1 |
| 20160354244 | Horvath et al. | Dec 2016 | A1 |
| 20160354245 | Horvath et al. | Dec 2016 | A1 |
| 20170172797 | Horvath et al. | Jun 2017 | A1 |
| 20170172798 | Horvath et al. | Jun 2017 | A1 |
| 20170172799 | Horvath | Jun 2017 | A1 |
| 20170348150 | Horvath et al. | Dec 2017 | A1 |
| Number | Date | Country |
|---|---|---|
| 1402625 | Mar 2003 | CN |
| 101677823 | Mar 2010 | CN |
| 102481171 | May 2012 | CN |
| 102510746 | Jun 2012 | CN |
| 2 296 663 | Jul 1996 | GB |
| 2009-542370 | Dec 2009 | JP |
| 2313315 | Dec 2007 | RU |
| 2482822 | May 2013 | RU |
| WO-9823237 | Jun 1998 | WO |
| WO-2000056255 | Sep 2000 | WO |
| WO-200274052 | Sep 2002 | WO |
| WO-2007087061 | Aug 2007 | WO |
| WO-2008005873 | Jan 2008 | WO |
| WO 2011155922 | Dec 2011 | WO |
| WO 2016023942 | Feb 2016 | WO |
| WO 2016159999 | Oct 2016 | WO |
| Entry |
|---|
| Horvath, U.S. Appl. No. 15/703,802, “Intraocular Shunt Implantation,” filed Sep. 13, 2017. |
| Horvath, U.S. Appl. No. 15/807,503, “Manually Adjustable Intraocular Flow Regulation,” filed Nov. 8, 2017. |
| U.S. Appl. No. 11/771,805, filed Jun. 29, 2007, 2008/0108933. |
| U.S. Appl. No. 12/946,572, filed Nov. 15, 2010, U.S. Pat. No. 8,852,256. |
| U.S. Appl. No. 12/946,542, filed Nov. 15, 2010, 2012/0123316. |
| U.S. Appl. No. 12/946,210, filed Nov. 15, 2010, U.S. Pat. No. 8,308,701. |
| U.S. Appl. No. 12/946,222, filed Nov. 15, 2010, 2012/0123434. |
| U.S. Appl. No. 12/946,240, filed Nov. 15, 2010, U.S. Pat. No. 8,828,070. |
| U.S. Appl. No. 12/946,251, filed Nov. 15, 2010, U.S. Pat. No. 9,095,411. |
| U.S. Appl. No. 12/946,263, filed Nov. 15, 2010, U.S. Pat. No. 8,801,766. |
| U.S. Appl. No. 12/946,351, filed Nov. 15, 2010, 2012/0123315. |
| U.S. Appl. No. 12/946,556, filed Nov. 15, 2010, 2012/0123317. |
| U.S. Appl. No. 13/314,927, filed Dec. 8, 2011, 2012/0197175. |
| U.S. Appl. No. 12/946,645, filed Nov. 15, 2010, U.S. Pat. No. 8,721,702. |
| U.S. Appl. No. 12/946,653, filed Nov. 15, 2010, U.S. Pat. No. 8,663,303. |
| U.S. Appl. No. 12/946,565, filed Nov. 15, 2010, U.S. Pat. No. 8,974,511. |
| U.S. Appl. No. 13/336,758, filed Dec. 23, 2011, U.S. Pat. No. 8,852,137 |
| U.S. Appl. No. 13/336,803, filed Dec. 23, 2011, U.S. Pat. No. 8,758,290 |
| U.S. Appl. No. 13/895,170, filed May 15, 2013, 2013/0253406. |
| U.S. Appl. No. 13/952,543, filed Jul. 26, 2013, U.S. Pat. No. 9,017,276. |
| U.S. Appl. No. 14/191,340, filed Feb. 26, 2014, 2014/0180189. |
| U.S. Appl. No. 14/263,957, filed Apr. 28, 2014, 2014/0236065. |
| U.S. Appl. No. 14/313,970, filed Jun. 24, 2014, 2015/0011926. |
| U.S. Appl. No. 15/153,630, filed May 12, 2016, Not Yet Published. |
| U.S. Appl. No. 15/153,646, filed May 12, 2016, Not Yet Published. |
| U.S. Appl. No. 15/153,648, filed May 12, 2016, Not Yet Published. |
| U.S. Appl. No. 15/153,651, filed May 12, 2016, Not Yet Published. |
| Coran, (editor in chief), “Pediatric Surgery,” Elsevier Saunders, published Feb. 14, 2012, 7th Edition, vol. 1, Chapter 128, pp. 1673-1697. |
| Quere, “Fluid Coating on a Fiber,” Annu. Rev. Fluid Mech. 1999, 31:347-84. |
| U.S. Appl. No. 15/153,630, filed May 12, 2016. |
| U.S. Appl. No. 15/153,648, filed May 12, 2016. |
| U.S. Appl. No. 15/153,651, filed May 12, 2016. |
| Number | Date | Country | |
|---|---|---|---|
| 20160256318 A1 | Sep 2016 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 14313970 | Jun 2014 | US |
| Child | 15153646 | US | |
| Parent | 12946645 | Nov 2010 | US |
| Child | 14263957 | US | |
| Parent | 12946653 | Nov 2010 | US |
| Child | 14191340 | US | |
| Parent | PCT/US2011/060820 | Nov 2011 | US |
| Child | 13895170 | US | |
| Parent | 12946210 | Nov 2010 | US |
| Child | PCT/US2011/060820 | US | |
| Parent | 12946542 | Nov 2010 | US |
| Child | 13952543 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 12946572 | Nov 2010 | US |
| Child | 14313970 | US | |
| Parent | 12946222 | Nov 2010 | US |
| Child | 12946572 | US | |
| Parent | 12946240 | Nov 2010 | US |
| Child | 12946222 | US | |
| Parent | 12946251 | Nov 2010 | US |
| Child | 12946240 | US | |
| Parent | 12946263 | Nov 2010 | US |
| Child | 12946251 | US | |
| Parent | 13314927 | Dec 2011 | US |
| Child | 12946263 | US | |
| Parent | 12946351 | Nov 2010 | US |
| Child | 13314927 | US | |
| Parent | 12946556 | Nov 2010 | US |
| Child | 14313970 | US | |
| Parent | 14263957 | Apr 2014 | US |
| Child | 12946556 | US | |
| Parent | 14191340 | Feb 2014 | US |
| Child | 14313970 | US | |
| Parent | 12946565 | Nov 2010 | US |
| Child | 14313970 | US | |
| Parent | 13336758 | Dec 2011 | US |
| Child | 12946565 | US | |
| Parent | 12946351 | Nov 2010 | US |
| Child | 13336758 | US | |
| Parent | 12946222 | Nov 2010 | US |
| Child | 12946351 | US | |
| Parent | 13336803 | Dec 2011 | US |
| Child | 14313970 | US | |
| Parent | 12946351 | Nov 2010 | US |
| Child | 13336803 | US | |
| Parent | 12946222 | Nov 2010 | US |
| Child | 12946351 | US | |
| Parent | 13895170 | May 2013 | US |
| Child | 14313970 | US | |
| Parent | 13952543 | Jul 2013 | US |
| Child | 14313970 | US |
